

DELIBERA DEL DIRETTORE GENERALE**375 / 2021 del 03/11/2021**

Oggetto: RECEPIMENTO DGR N. XI/5411 DEL 25.10.2021 "INIZIATIVA DIRETTA DI COOPERAZIONE INTERNAZIONALE AI SENSI DELLA L.R. 20/89: "PROGETTO SIERRA LEONE - VACCINAZIONE ANTI COVID-19" - (DI CONCERTO CON IL VICE PRESIDENTE MORATTI), E NOMINA DEI PROFESSIONISTI COMPONENTI DEL CONNESSO GRUPPO DI LAVORO OPERATIVO

OGGETTO: RECEPIMENTO DGR N. XI/5411 DEL 25.10.2021 "INIZIATIVA DIRETTA DI COOPERAZIONE INTERNAZIONALE AI SENSI DELLA L.R. 20/89: "PROGETTO SIERRA LEONE - VACCINAZIONE ANTI COVID-19" - (DI CONCERTO CON IL VICE PRESIDENTE MORATTI), E NOMINA DEI PROFESSIONISTI COMPONENTI DEL CONNESSO GRUPPO DI LAVORO OPERATIVO

vista la seguente proposta di deliberazione n. 663/2021, avanzata dal Direttore della Struttura Complessa Affari Generali e Legali

IL DIRETTORE GENERALE

VISTE:

- la legge n. 125/2014 "disciplina generale sulla cooperazione internazionale per lo sviluppo";
- il "Documento Triennale di Programmazione ed Indirizzo per la cooperazione internazionale allo sviluppo" del Ministero degli Affari Esteri e della Cooperazione Internazionale che individua, tra le priorità, gli interventi umanitari e di post-emergenza;
- l'art. 3 L.R. n. 20/1989 "la Lombardia per la pace e la cooperazione allo sviluppo" che prevede che Regione Lombardia approvi progetti di attività di cooperazione elaborati anche su iniziativa delle O.N.G. che operano nel campo della cooperazione dei paesi in via di sviluppo, di associazioni, fondazioni e di altri soggetti;
- le "Linee guida per la cooperazione internazionale di Regione Lombardia – XI Legislatura", approvate con D.G.R. n. 951/2018, che prevedono:
 - tra gli obiettivi, iniziative a sostegno delle popolazioni, in caso di situazioni di emergenza, generate, tra gli altri eventi, anche da epidemie;
 - tra le tipologie di intervento, progetti di iniziativa regionale diretta, realizzati in risposta alla necessità di aiuto umanitario, a seguito di interventi sanitari umanitari, con la messa a disposizione di competenze ed esperienze individuate negli Enti del "sistema allargato" del territorio lombardo;
 - tra le aree geografiche d'intervento, l'Africa Sub Sahariana;

PRESO ATTO:

- del Decreto del Presidente di Regione Lombardia n. 692 del 5.2.2021, tramite il quale sono stati costituiti: il Comitato Guida Vaccinazioni anti COVID-19, che coordina a livello istituzionale la campagna vaccinale e ne monitora l'andamento, alla luce della rilevanza strategica e della complessità organizzativa da porre in essere per far fronte all'epidemia in corso, e il Comitato Esecutivo Vaccinazioni anti COVID-19, al fine di dare operatività alle decisioni assunte nel Comitato Guida nel quale risulta componente in qualità di D.G. di AREU dott. Zoli;
- della deliberazione AREU n. 78 del 5.3.2021 di "presa d'atto dell'insediamento del Comitato Esecutivo vaccinazioni anti Covid-19 presso gli uffici della sede centrale dell'AREU";
- del Decreto del Presidente di Regione Lombardia n. 9227 del 7.7.2021, con il quale nell'ambito del comitato esecutivo è stato attribuito al D.G. di AREU, il coordinamento

operativo in raccordo con la DG Welfare;

- della DGR n. XI/5411 DEL 25.10.2021 ad oggetto "iniziativa diretta di cooperazione internazionale ai sensi della L.R. 20/89: "Progetto Sierra Leone - vaccinazione anti Covid-19" - (di concerto con il Vice Presidente Moratti), con la quale è stato approvato il "Progetto Sierra Leone – vaccinazione anti Covid19, trasmesso da AREU a Regione Lombardia con nota prot. n. 16839 del 18.10.2021;

EVIDENZIATO che l'iniziativa umanitaria promossa da Regione Lombardia, di cui alla DGR n. XI/5411/2021, ha l'obiettivo di attivare una campagna di vaccinazione anti SARS-CoV-2/Covid-19 nello stato africano della Sierra Leone, per fasce d'età e segmenti di popolazione target, con l'obiettivo di immunizzare entro la primavera 2022 almeno il 10% della popolazione vaccinabile di tale Stato (ovvero 500.000 persone su un target di circa 5 milioni di abitanti), concentrando le attività soprattutto nella capitale Freetown;

DATO ATTO CHE, nell'ambito di tale progetto, sotto il profilo esecutivo, AREU è proposta quale Ente operativo, per conto di Regione Lombardia, in particolare per il reclutamento presso Enti del S.S.S.R., organizzazioni della società civile o soggetti privati, dei professionisti che dispongano delle adeguate competenze per sostenere iniziative realizzate in ambito di emergenza umanitaria, di particolare gravità e a beneficio della popolazione interessata, quale quella individuata nel Progetto sopra citato;

RILEVATO che a tal fine AREU ritiene di individuare i seguenti professionisti quali componenti del Gruppo di Lavoro operativo:

- dipendenti di AREU:
 - Alberto Zoli, Direttore Generale - Coordinatore operativo, responsabile del progetto
 - Elisabetta Thea Scognamiglio Pasini - Dirigente Medico con specializzazione in Igiene Epidemiologica e Sanità Pubblica presso la S.C. Direzione Medico Organizzativa;
 - Gianluca Chiodini - referente tecnico-operativo e logistico del Nucleo Maxiemergenze-BCR-Grandi Eventi
 - Mimma di Benedetto – farmacista ospedaliero in quiescenza
 - Andrea Albonico - Direttore del Dipartimento Amministrativo e della S.C. Affari Generali e Legali
- tra i dipendenti di altri Enti del S.S.R., organizzazioni della società civile o soggetti privati:
 - Guido Bertolaso - Coordinatore esecutivo
 - Agostino Miozzo - Coordinatore esecutivo
 - Catia Rosanna Borriello - esperto vaccinatore, tecnico scientifico (Direttore UOC Vaccinazioni ASST Fatebenefratelli Sacco, in distacco presso Direzione Generale Welfare di Regione Lombardia – U.O. Prevenzione)
 - Marco Magrini - rapporti con struttura commissariale e gestione della catena di distribuzione dei vaccini (Direttore del Dipartimento di Prevenzione Veterinario ATS Insubria)
 - Davide Zenoni - Direttore UOC Farmacia (ASST Nord Milano)
 - Roberto Moretti - clinico infettivologo, pediatra (ATS Bergamo)

- Danilo Cereda - Medico specialista igiene sanità pubblica, direttore Struttura Complessa area malattie infettive e vaccinazioni (ATS Valpadana)
- Roberto Laffi - Direttore Generale Territorio e Protezione Civile (Regione Lombardia)
- Maria Luisa Scalise – Direttore di Funzione specialistica Unità Organizzativa Relazioni internazionali, esterne e cerimoniale (Regione Lombardia)
- Giuseppina Valenti - struttura comunicazione e sviluppo modello di presa in carico (Direzione Generale Welfare di Regione Lombardia)
- Michela Secol – Coordinatore segreteria progetto (staff Presidenza Regione Lombardia)

PRESO ATTO che la DGR n. XI/5411 del 25/10/2021 di approvazione del "Progetto Sierra Leone - vaccinazione anti Covid-19" prevede:

- una spesa complessiva di 250.000 per l'intera durata del progetto, la cui conclusione è programmata per il 31.12.2022;
- che il contributo verrà erogato per ogni annualità con la seguente modalità:
 - il 50% del contributo dell'annualità 2021, ovvero 50.000 € di spese correnti, verrà erogato a titolo di anticipo,
 - il restante 50% relativo all'anno 2021, ovvero 50.000 € di spese di investimento, a seguito di presentazione, entro il 31 dicembre 2021, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute;
 - il 50% del contributo dell'annualità 2022, ovvero 75.000 € di spese correnti, verrà erogato a titolo di anticipo contestualmente all'erogazione del saldo dell'annualità del 2021;
 - il saldo relativo all'anno 2022, ovvero 75.000 € di spese di investimento, verrà erogato a seguito di presentazione, entro il 31 dicembre 2022, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute, accompagnata da una relazione finale attestante i risultati complessivi raggiunti dal progetto;
- che AREU dovrà presentare una rendicontazione tecnica e finanziaria per ogni annualità delle spese sostenute con giustificativi di spesa e di pagamento, con indicazione dei risultati annuali raggiunti; a fine progetto tale rendicontazione annuale dovrà essere accompagnata da una relazione finale attestante i risultati complessivi raggiunti;
- ai componenti del Gruppo di Lavoro operativo sarà riconosciuto il solo rimborso delle spese documentate di vitto/alloggio/viaggio e di altra natura strettamente connesse alla partecipazione e all'esecuzione del progetto;

RILEVATO per quanto sopra, di dover inoltrare ai Direttori Generali degli Enti del SSR di appartenenza dei suddetti Professionisti, apposita comunicazione di individuazione degli stessi per le finalità sopra meglio specificate quali componenti del Gruppo di Lavoro operativo;

PRESO ATTO che il Proponente del procedimento attesta la completezza, la regolarità tecnica e la legittimità del presente provvedimento;

ACQUISITI i pareri favorevoli del Direttore Amministrativo e del Direttore Sanitario, resi per

quanto di specifica competenza ai sensi dell'art. 3 del D.Lgs. n. 502/1992 e s.m.i.;

DELIBERA

Per tutti i motivi in premessa indicati e integralmente richiamati:

1. di recepire il contenuto della DGR della Lombardia n. XI/5411 del 25.10.2021, allegata al presente provvedimento quale sua parte integrante e sostanziale, ad oggetto "iniziativa diretta di cooperazione internazionale ai sensi della l.r. 20/89: "progetto Sierra Leone - vaccinazione anti Covid-19" - (di concerto con il Vice Presidente Moratti);
2. di nominare i seguenti professionisti quali componenti del Gruppo di Lavoro operativo per la realizzazione del citato progetto:
 - tra i dipendenti di AREU:
 - Alberto Zoli, Direttore Generale - Coordinatore operativo e responsabile del progetto
 - Elisabetta Thea Scognamiglio Pasini - Dirigente Medico con specializzazione in Igiene Epidemiologica e Sanità Pubblica presso la S.C. Direzione Medico Organizzativa;
 - Gianluca Chiodini - Referente tecnico-operativo e logistico del Nucleo Maxiemergenze-BCR-Grandi Eventi
 - Mimma di Benedetto – farmacista ospedaliero in quiescenza
 - Andrea Albonico - Direttore del Dipartimento Amministrativo e della S.C. Affari Generali e Legali
 - tra i dipendenti di altri Enti del S.S.R., organizzazioni della società civile o soggetti privati:
 - Guido Bertolaso - Coordinatore esecutivo
 - Agostino Miozzo - Coordinatore esecutivo
 - Catia Rosanna Borriello - esperto vaccinator, tecnico scientifico (Direttore UOC Vaccinazioni ASST Fatebenefratelli Sacco, in distacco presso Direzione Generale Welfare di Regione Lombardia – U.O. Prevenzione)
 - Marco Magrini - rapporti con struttura commissariale e gestione della catena di distribuzione dei vaccini (Direttore del Dipartimento di Prevenzione Veterinario ATS Insubria)
 - Davide Zenoni - Direttore UOC Farmacia (ASST Nord Milano)
 - Roberto Moretti - clinico infettivologo, pediatra (ATS Bergamo)
 - Danilo Cereda - Medico specialista igiene sanità pubblica, direttore Struttura Complessa area malattie infettive e vaccinazioni (ATS Valpadana)
 - Roberto Laffi - Direttore Generale Territorio e Protezione Civile (Regione Lombardia)
 - Maria Luisa Scalise – Direttore di Funzione specialistica Unità Organizzativa Relazioni internazionali, esterne e cerimoniale (Regione Lombardia)
 - Giuseppina Valenti - struttura comunicazione e sviluppo modello di presa in carico (Direzione Generale Welfare di Regione Lombardia)

- Michela Secol – Coordinatore segreteria progetto (staff Presidenza Regione Lombardia)
- 3. di prendere atto che la DGR n. XI/5411 del 25/10/2021 di approvazione del “Progetto Sierra Leone - vaccinazione anti Covid-19” prevede:
 - una spesa complessiva di 250.000 per l'intera durata del progetto, la cui conclusione è programmata per il 31.12.2022;
 - che il contributo verrà erogato per ogni annualità con la seguente modalità:
 - il 50% del contributo dell'annualità 2021, ovvero 50.000 € di spese correnti, verrà erogato a titolo di anticipo,
 - il restante 50% relativo all'anno 2021, ovvero 50.000 € di spese di investimento, a seguito di presentazione, entro il 31 dicembre 2021, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute;
 - il 50% del contributo dell'annualità 2022, ovvero 75.000 € di spese correnti, verrà erogato a titolo di anticipo contestualmente all'erogazione del saldo dell'annualità del 2021;
 - il saldo relativo all'anno 2022, ovvero 75.000 € di spese di investimento, verrà erogato a seguito di presentazione, entro il 31 dicembre 2022, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute, accompagnata da una relazione finale attestante i risultati complessivi raggiunti dal progetto;
- 4. che AREU dovrà presentare una rendicontazione tecnica e finanziaria per ogni annualità delle spese sostenute con giustificativi di spesa e di pagamento, con indicazione dei risultati annuali raggiunti; a fine progetto tale rendicontazione annuale dovrà essere accompagnata da una relazione finale attestante i risultati complessivi raggiunti;
- 5. di dare atto che gli oneri conseguenti verranno registrati ai competenti conti del bilancio aziendale secondo natura, coerentemente con le previste rendicontazioni predisposte a cura del responsabile del procedimento e verranno finanziati con il contributo ad hoc stanziato con la DGR n. XI/5411 del 25/10/2021;
- 6. di prevedere che ai componenti del Gruppo di Lavoro operativo sarà riconosciuto il solo rimborso delle spese documentate di vitto/alloggio/viaggio e di altra natura strettamente connesse alla partecipazione e all'esecuzione del progetto;
- 7. di prevedere, per quanto sopra, di dover inoltrare ai Direttori Generali degli Enti del SSR di appartenenza dei suddetti professionisti, apposita comunicazione di individuazione degli stessi per le finalità sopra meglio specificate quali componenti del Gruppo di Lavoro operativo;
- 8. di dare atto che, ai sensi della L. n. 241/1990, responsabile del presente procedimento è il dott. Andrea Albonico, Direttore della S.C. Affari Generali e Legali;
- 9. di disporre che vengano rispettate tutte le prescrizioni inerenti alla pubblicazione sul portale web aziendale di tutte le informazioni e i documenti richiesti e necessari ai sensi del D.Lgs. n. 33/2013 e s.m.i., c.d. Amministrazione Trasparente;
- 10. di disporre la pubblicazione del presente provvedimento all'Albo Pretorio on line dell'Agenzia, dando atto che lo stesso è immediatamente esecutivo (ex art. 32 comma 5 L. n. 69/2009 s.m.i. e art. 17 comma 6 L.R. n. 33/2009).

La presente delibera è sottoscritta digitalmente, ai sensi dell'art. 21 D.Lgs. n. 82/2005 e s.m.i., da:

Il Direttore Amministrativo Luca Filippo Maria Stucchi

Il Direttore Sanitario Giuseppe Maria Sechi

Il Direttore Generale Alberto Zoli



Regione Lombardia

LA GIUNTA

DELIBERAZIONE N° XI / 5411

Seduta del 25/10/2021

Presidente

ATTILIO FONTANA

Assessori regionali

LETIZIA MORATTI *Vice Presidente*

STEFANO BOLOGNINI

DAVIDE CARLO CAPARINI

RAFFAELE CATTANEO

RICCARDO DE CORATO

MELANIA DE NICHILLO RIZZOLI

PIETRO FORONI

STEFANO BRUNO GALLI

GUIDO GUIDESI

ALESSANDRA LOCATELLI

LARA MAGONI

ALESSANDRO MATTINZOLI

FABIO ROLFI

FABRIZIO SALA

MASSIMO SERTORI

CLAUDIA MARIA TERZI

Con l'assistenza del Segretario Enrico Gasparini

Su proposta del Presidente Attilio Fontana di concerto con l'Assessore Letizia Moratti

Oggetto

INIZIATIVA DIRETTA DI COOPERAZIONE INTERNAZIONALE AI SENSI DELLA L.R. 20/89: "PROGETTO SIERRA LEONE - VACCINAZIONE ANTI COVID-19" - (DI CONCERTO CON IL VICE PRESIDENTE MORATTI)

Il Segretario Generale

Antonello Turturiello

Si esprime parere di regolarità amministrativa ai sensi dell'art.4, comma 1, l.r. n.17/2014:

Il Vice Segretario Generale

Pier Attilio Superti

Il Direttore di Funzione Specialistica

Maria Luisa Scalise

Il Direttore Generale

Giovanni Pavesi

L'atto si compone di 68 pagine

di cui 60 pagine di allegati

parte integrante



Regione Lombardia

LA GIUNTA

VISTI:

- la legge n. 125 dell'11 agosto 2014 "Disciplina generale sulla cooperazione internazionale per lo sviluppo";
- il "Documento Triennale di Programmazione ed Indirizzo per la cooperazione internazionale allo sviluppo" del Ministero degli Affari Esteri e della Cooperazione Internazionale che individua, tra le priorità, gli interventi umanitari e di post-emergenza;

VISTE:

- la legge regionale n. 20 del 5 giugno 1989 "La Lombardia per la pace e la cooperazione allo sviluppo" che prevede all'art. 3 che Regione Lombardia approva progetti di attività di cooperazione elaborati anche su iniziativa delle organizzazioni non governative che operano nel campo della cooperazione dei paesi in via di sviluppo, di associazioni, fondazioni e di altri soggetti;
- le "Linee guida per la cooperazione internazionale di Regione Lombardia – XI Legislatura", approvate con D.G.R. n. 951 dell'11 dicembre 2018, che prevedono:
 - tra gli obiettivi, iniziative a sostegno delle popolazioni, in caso di situazioni di emergenza, generate da gravi calamità naturali, conflitti armati, epidemie;
 - tra le tipologie di intervento, progetti di iniziativa regionale diretta, realizzati in risposta alla necessità di aiuto umanitario, a seguito di calamità naturali o belliche; interventi sanitari umanitari; progetti realizzati con la messa a disposizione di competenze ed esperienze individuate negli Enti del "sistema allargato" del territorio lombardo;
 - tra le aree geografiche d'intervento, l'Africa Sub Sahariana;

RICHIAMATO Il Programma Regionale di Sviluppo della XI legislatura, approvato con d.c.r. 10 luglio 2018, n. 64 che prevede tra i risultati attesi la realizzazione di azioni a sostegno del miglioramento delle condizioni economiche e sociali nei Paesi in via di sviluppo (risultato atteso 34, istit. 19);

VISTE inoltre:

- la legge regionale n. 30, del 27 dicembre 2006, e successive modificazioni, che ha istituito il Sistema Regionale allargato e ha definito i soggetti che lo costituiscono, tra i quali AREU – Agenzia Regionale Emergenza Urgenza;
- la legge regionale n. 33 del 30 dicembre 2009, che all'articolo 16 disciplina le funzioni di AREU quale Agenzia Sanitaria;



Regione Lombardia

LA GIUNTA

PRESO ATTO del:

- Decreto del Presidente di Regione Lombardia n. 692 del 5 febbraio 2021, tramite il quale sono stati costituiti:
 - o il Comitato Guida Vaccinazioni anti COVID-19, che coordina a livello istituzionale la campagna vaccinale e ne monitora l'andamento, alla luce della rilevanza strategica e della complessità organizzativa da porre in essere per far fronte all'epidemia in corso;
 - o il Comitato Esecutivo Vaccinazioni anti COVID-19, al fine di dare operatività alle decisioni assunte nel Comitato Guida nel quale risulta componente in qualità di Direttore generale dell'Agenzia Regionale Emergenza Urgenza il dr. Alberto Zoli;
- Decreto del Presidente di Regione Lombardia n. 9227 del 7 luglio 2021, con il quale nell'ambito del comitato esecutivo è stato attribuito al dr. Alberto Zoli, direttore generale di AREU, il coordinamento operativo in raccordo con la DG Welfare;

CONSIDERATO che Regione Lombardia intende perseguire i suddetti obiettivi, anche in collaborazione con i soggetti del sistema regionale allargato, che dispongono delle adeguate competenze e *know how*, sostenendo iniziative dirette realizzate in aree caratterizzate da emergenza umanitaria di particolare gravità che possano contribuire al miglioramento delle condizioni di vita delle comunità interessate;

DATO ATTO che il Ministro della Salute e Sanità della Sierra Leone ha chiesto, con lettera indirizzata al Consolato Italiano in Sierra Leone, al Governo italiano di essere supportato nelle vaccinazioni anti COVID e rafforzare il sistema sanitario del Paese;

CONSIDERATO che:

- la Sierra Leone, in base alla classificazione delle Nazioni Unite, rientra nella lista dei 46 *Least Developed Countries* (paesi meno sviluppati), che raggruppa gli Stati ritenuti fortemente svantaggiati nel loro processo di sviluppo, per ragioni strutturali, storiche e anche geografiche e che pertanto sono, più di altri soggetti, a rischio di grave povertà e sono caratterizzati dalla elevata vulnerabilità agli shock economici e naturali e in particolare alle malattie trasmissibili;
- i *Least Developed Countries* necessitano pertanto del massimo grado di attenzione da parte della comunità internazionale;
- la Sierra Leone è al 181° posto, per prodotto interno lordo pro capite su 198



Regione Lombardia

LA GIUNTA

Stati classificati;

- il sistema sanitario della Sierra Leone è in condizioni di grave fragilità e l'accesso alle strutture pubbliche, oltre che al sistema sanitario, non è garantito alla popolazione;
- si registra una presenza molto ridotta di medici e personale sanitario specializzato nelle strutture del Paese;
- secondo i dati dell'Organizzazione Mondiale della Sanità, la mortalità infantile e materna della Sierra Leone è tra le più alte al mondo;
- in Sierra Leone, in base ai dati dell'Organizzazione Mondiale della Sanità, al 4 ottobre 2021 sono state somministrate 236.465 dosi di vaccino per un totale di 43.907 persone vaccinate, che corrispondono a una percentuale dello 0,56% sul totale della popolazione;

VALUTATO che la bassa percentuale di vaccinazioni e le carenze del sistema sanitario rendono necessaria un'azione di sostegno alla campagna vaccinale e di contrasto al Covid-19 per contribuire alla riduzione della pressione sulle strutture ospedaliere e sul personale sanitario, evitando possibili ripercussioni da epidemie da Coronavirus;

CONSIDERATO pertanto che, alla luce di quanto sopra descritto, è urgente far fronte alla situazione di emergenza sanitaria in Sierra Leone, al fine di sostenere il miglioramento delle condizioni sociali e di vita, con particolare salvaguardia dei diritti di cura delle comunità locali;

VISTO il "Progetto Sierra Leone - vaccinazione anti COVID-19" (allegato 1 parte integrante e sostanziale del presente provvedimento), protocollo A1.2021.0428568 presentato dal coordinatore operativo Unità di crisi vaccinale e Direttore generale dell'Agenzia Regionale Emergenza Urgenza (AREU);

CONSIDERATO che il progetto:

- ha come obiettivo la realizzazione di un progetto pilota che miri a immunizzare, entro la primavera del 2022, almeno il 10% della popolazione della Sierra Leone, vaccinando 500.000 persone su un target di circa 5 milioni;
- si compone di due fasi:
 1. invio del team composto da operatori sanitari ed esperti in logistica in Sierra Leone per la verifica della fattibilità del progetto;
 2. avvio e realizzazione del progetto, con l'invio del team sanitario e logistico, e delle attrezzature e dispositivi necessari alla buona riuscita



Regione Lombardia

LA GIUNTA

della campagna vaccinale;

PRESO ATTO:

- che il progetto in questione è stato già condiviso con il Ministero degli Affari Esteri e della Cooperazione Internazionale e il Ministero della Salute, nonché con il Governo della Sierra Leone per tramite della rappresentanza italiana in Sierra Leone;
- degli accordi intercorsi tra AREU e il “Commissario straordinario per l'attuazione e il coordinamento delle misure di contenimento e contrasto dell'emergenza epidemiologica COVID-19 e per l'esecuzione della campagna vaccinale nazionale” ai fini della fornitura e del trasporto dei vaccini necessari alla realizzazione dell'iniziativa;

VISTO che il sopracitato progetto prevede per la sua realizzazione il coinvolgimento di diversi soggetti sia pubblici, Enti del Sistema sociosanitario regionale, sia organizzazioni della società civile (es. ong) e sia privati, al fine di reclutare i professionisti necessari;

DATO ATTO che per le eventuali fasi di implementazione del progetto potranno essere condotte da AREU missioni a Bruxelles per il coinvolgimento delle istituzioni europee;

VALUTATO che il suddetto progetto (allegato 1 parte integrante e sostanziale del presente provvedimento) è in grado di rispondere efficacemente all'urgenza di interventi concreti a favore della popolazione locale garantendo il miglioramento delle condizioni dei destinatari, con particolare riferimento alla situazione sanitaria e nella fattispecie alle misure di contrasto al Covid-19;

RITENUTO pertanto - in conformità alle priorità individuate dalla programmazione nazionale e regionale, all'emergenza in corso e sulla base della disponibilità delle risorse destinate a tali interventi sull'annualità 2021 e 2022 del bilancio regionale - di approvare il suddetto progetto per una somma complessiva di 250.000 euro a valere sui seguenti capitoli, che presentano la necessaria disponibilità di cassa a seguito di variazione di bilancio e prelievo dal fondo spese impreviste, richiesti con nota protocollo A1.2021.0424567 del 14/10/2021 e approvata con dgr n. 5404 del 18/10/2021:

- euro 50.000 a valere sul capitolo 19.01.104.15110 del bilancio 2021;
- euro 50.000 a valere sul capitolo 19.01.203.15111 del bilancio 2021;
- euro 75.000 a valere sul capitolo 19.01.104.15110 del bilancio 2022;



Regione Lombardia

LA GIUNTA

- euro 75.000 a valere sul capitolo 19.01.203.15111 del bilancio 2022;

STABILITO che:

- il suddetto progetto dovrà essere realizzato entro il 31 dicembre 2022;
- AREU dovrà presentare una rendicontazione tecnica e finanziaria per ogni annualità delle spese sostenute con giustificativi di spesa e di pagamento, con indicazione dei risultati annuali raggiunti;
- a fine progetto tale rendicontazione annuale dovrà essere accompagnata da una relazione finale attestante i risultati complessivi raggiunti;

RITENUTO inoltre che il contributo verrà erogato per ogni annualità con la seguente modalità:

- il 50% del contributo dell'annualità 2021, ovvero 50.000 € di spese correnti, verrà erogato a titolo di anticipo, a seguito di approvazione del presente provvedimento;
- il restante 50% relativo all'anno 2021, ovvero 50.000 € di spese di investimento, a seguito di presentazione, entro il 31 dicembre 2021, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute;
- il 50% del contributo dell'annualità 2022, ovvero 75.000 € di spese correnti, verrà erogato a titolo di anticipo contestualmente all'erogazione del saldo dell'annualità del 2021;
- il saldo relativo all'anno 2022, ovvero 75.000 € di spese di investimento, verrà erogato a seguito di presentazione, entro il 31 dicembre 2022, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute, accompagnata da una relazione finale attestante i risultati complessivi raggiunti dal progetto;

DATO ATTO che il Dirigente pro tempore della Unità organizzativa Relazioni internazionali ed esterne provvederà con atti successivi all'approvazione del presente provvedimento a impegnare le risorse previste in favore del suddetto beneficiario e a liquidarle previa istruttoria della rendicontazione pervenuta;

STABILITO che il sostegno ai progetti di cooperazione internazionale di aiuto umanitario non rientra nell'ambito di applicazione delle norme UE in tema di aiuti di Stato in quanto le attività da cofinanziare non configurano l'esercizio di attività economica;



Regione Lombardia

LA GIUNTA

VISTE:

- la L.R. 34/1978 e successive modifiche e integrazioni, nonché il regolamento di contabilità e la legge di approvazione del bilancio di previsione dell'anno in corso;
- la L.R. 7 luglio 2008, n. 20 "Testo unico delle leggi regionali in materia di organizzazione e personale", nonché i provvedimenti organizzativi della XI legislatura;

DATO ATTO che, contestualmente alla data di adozione del presente atto, si provvede alla pubblicazione di cui agli artt. 26 e 27 del D.Lgs. 14 marzo 2013, n. 33;

All'unanimità dei voti, espressi nelle forme di legge;

DELIBERA

1. di approvare il "Progetto Sierra Leone - vaccinazione anti Covid-19" presentato dal coordinatore operativo Unità di crisi vaccinale e Direttore generale dell'Agenzia Regionale Emergenza Urgenza – AREU, (allegato 1 parte integrante e sostanziale del presente provvedimento), prevedendo una spesa complessiva di 250.000 euro a valere sui seguenti capitoli, che presentano la necessaria disponibilità di cassa a seguito di variazione di bilancio e prelievo dal fondo spese impreviste, richiesti con nota protocollo A1.2021.0424567 del 14/10/2021 e approvata con dgr n. 5404 del 18/10/2021:
 - euro 50.000 a valere sul capitolo 19.01.104.15110 del bilancio 2021;
 - euro 50.000 a valere sul capitolo 19.01.203.15111 del bilancio 2021;
 - euro 75.000 a valere sul capitolo 19.01.104.15110 del bilancio 2022;
 - euro 75.000 a valere sul capitolo 19.01.203.15111 del bilancio 2022;
2. di prevedere che il contributo verrà erogato per ogni annualità con la seguente modalità:
 - il 50% del contributo dell'annualità 2021, ovvero 50.000 € di spese correnti, verrà erogato a titolo di anticipo, a seguito di approvazione del presente provvedimento;
 - il restante 50% relativo all'anno 2021, ovvero 50.000 € di spese di



Regione Lombardia
LA GIUNTA

-
- investimento, a seguito di presentazione, entro il 31 dicembre 2021, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute;
- il 50% del contributo dell'annualità 2022, ovvero 75.000 € di spese correnti, verrà erogato a titolo di anticipo contestualmente all'erogazione del saldo dell'annualità del 2021;
 - il saldo relativo all'anno 2022, ovvero 75.000 € di spese di investimento, verrà erogato a seguito di presentazione, entro il 31 dicembre 2022, di una relazione tecnico finanziaria delle attività annuali svolte e copia dei giustificativi di spesa e di pagamento delle spese sostenute, accompagnata da una relazione finale attestante i risultati complessivi raggiunti dal progetto;
3. di dare atto che il sopracitato progetto prevede per la sua realizzazione il coinvolgimento di diversi soggetti sia pubblici, Enti del Sistema sociosanitario regionale, sia organizzazioni della società civile (es. ong) e sia privati, al fine di reclutare i professionisti necessari;
4. di dare mandato al Dirigente pro tempore della Unità organizzativa Relazioni internazionali ed esterne di provvedere ai successivi atti di impegno e di liquidazione delle somme assegnate;
5. di stabilire che il sostegno ai progetti di cooperazione internazionale di aiuto umanitario non rientra nell'ambito di applicazione delle norme UE in tema di aiuti di Stato in quanto le attività da cofinanziare non configurano l'esercizio di attività economica;
6. di attestare che, contestualmente alla data di adozione del presente atto, si provvede alla pubblicazione di cui agli artt. 26 e 27 del D.Lgs. 14 marzo 2013, n. 33.

IL SEGRETARIO
ENRICO GASPARINI

Atto firmato digitalmente ai sensi delle vigenti disposizioni di legge

PROGETTO SIERRA LEONE - vaccinazione anti COVID-19

Popolazione totale (SSL Census - 2020 Projections, 2015)	8,2 milioni
Popolazione in stato di denutrizione (FAO STAT, 2018-2020)	2 milioni
Popolazione con apporto di cibo insufficiente (WFP, Sep 2021)	4,5 milioni
PIL pro capite (World Bank national accounts data, 2021)	484 USD

Il 40% della popolazione della Sierra Leone ha meno di 15 anni e il 50% meno di 20 anni. Il 5,9% della popolazione ha più di 65 anni. L'età media è di 19,4 anni.

La mortalità infantile della Sierra Leone è tra le più alte al mondo: malaria, malnutrizione, patologie delle vie respiratorie e infezioni gastrointestinali sono le principali cause di decesso tra i minori di cinque anni.

Secondo i dati dell'Organizzazione Mondiale della Sanità, in Sierra Leone il 21% dei bambini sotto i 5 anni è sottopeso e, su mille bambini nati vivi, 109 muoiono prima dei 5 anni¹.

Anche il tasso di mortalità materna è altissimo: si registrano 1360 decessi ogni 100mila nascite e il 36% dei decessi tra le donne dai 15 ai 49 anni è dovuto a complicanze legate alla gravidanza e al parto.

Nonostante la sanità nel Paese sia gratuita per i bambini al di sotto dei cinque anni e per le donne in stato di gravidanza o in allattamento, solo in pochi riescono effettivamente ad avere accesso alle cure in questo sistema di sanità pubblica.

SIERRA LEONE. COVID-19 E LA VACCINAZIONE MASSIVA

I pochi dati sul COVID in Sierra Leone individuano 6.396 casi confermati con 121 decessi dall'inizio della pandemia.² Sono certamente sottostimati in quanto non ci sono studi di siero-prevalenza ed il testing con tamponi è estremamente limitato.

In Africa la siero-prevalenza rilevata con studi su diversi campioni di popolazione, definisce una positività che varia da 0,4% a Capo Verde al 49% in Kenya;³ in ogni caso, pur nella scarsità di informazioni epidemiologiche la vaccinazione è da considerare uno strumento importantissimo conoscendo l'enorme impatto del potenziale epidemico del COVID e dell'andamento "a ondate" della trasmissione, nonché della potenziale insorgenza di varianti. **In allegato alcuni dati e un articolo sulla vaccinazione nei paesi in via di sviluppo.**

¹ Unicef Country Profile <https://data.unicef.org/country/sle/>

² <https://covid19.who.int/region/afro/country/sl>

³ Published: 24 June 2021 Understanding COVID-19 in Africa. Sofonias K. Tessema & John N. Nkengasong Nature Reviews Immunology volume 21, pages469–470 (2021)

L'effetto dell'infezione da Covid sulle comorbidità tipiche dei paesi tropicali non è ancora chiarito. Ma non c'è alcun dubbio sul fatto che sia auspicabile la vaccinazione massiva perché la debolezza strutturale del sistema sanitario, recentemente evidenziata dalla grave epidemia di Ebola durante la quale morirono 3,589 su 8,704 persone infettate nel 2014-2015, rafforza l'esigenza di adottare questo intervento di sanità pubblica.*

IL COVID-19 E LA VACCINAZIONE IN SIERRA LEONE

Con il sistema sanitario appena descritto si deve considerare la Sierra Leone come uno Stato target per procedere con una operazione di vaccinazione massiva e si deve individuare come primo passo un progetto pilota su un campione limitato della popolazione (500.000) concentrando le attività soprattutto nella capitale Freetown.

La presenza di medici in attività nel 2010 era di circa 2,5 medici ogni 10.000 abitanti⁴. Al 9 aprile 2020, c'erano 130 letti per pazienti Covid-19, 15 letti in terapia intensiva e 200 concentratori di ossigeno⁵.

Alla data del 29 Settembre 2021, risultano somministrate **236.465** dosi di vaccino anti SARS CoV2/COVID-19. Sono state vaccinate, con almeno una dose **192.558** persone e completamente vaccinati 43.907 cittadini⁶.

Pertanto, è indispensabile l'attivazione di una campagna di vaccinazione pilota anti SARS-CoV-2/Covid-19 per fasce d'età e segmenti di popolazione target.

QUALI ENTI COINVOLGERE

- Ministero Affari esteri e della Cooperazione Internazionale (per il tramite di Regione Lombardia)
- Ministero della Salute (per il tramite di Regione Lombardia)
- State House of Government - Ministry of Health & Sanitation, Programma EPI (per il tramite del Console Onorario a Freetown e della missione tecnica che si recherà in Sierra Leone)
- International Entities - WHO, UNFPA, UNICEF, Commissione Europea, DG ECHO (per il tramite della missione tecnica una volta avuta green light dalla Regione Lombardia e sentiti il Ministero Affari esteri e della Cooperazione Internazionale e il Ministero della Salute).
- Enti Operativi – AREU Agenzia Regionale della Emergenza e Urgenza della Regione Lombardia (capo fila del progetto), DG Welfare Regione Lombardia, Dg Protezione Civile Regione Lombardia, Struttura del Commissario straordinario per l'attuazione e il coordinamento delle misure di contenimento e contrasto dell'emergenza epidemiologica COVID-19 e per l'esecuzione della campagna vaccinale nazionale.
- Per il tramite di AREU, reclutamento dei professionisti necessari presso Enti del Sistema sociosanitario regionale e privati a contratto con il SSR o soggetti privati.
- ONG e altri enti - CUAMM, Emergency, COOPI, altri partner nazionali ed internazionali pubblici/privati.

⁴ <https://data.worldbank.org/indicator/SH.MED.PHYS.ZS?locations=SL>

⁵ <https://datapopalliance.org/covid19/c19globalsouthobservatory/sierra-leone/>

⁶ Dati WHO sito: <https://covid19.who.int/region/afro/country/sl> sito visitato il 08/10/2021 il valore coincide anche con quelli del sito <https://coronavirus.jhu.edu/region/sierra-leone> della John Hopkins University

*A seguito dell'epidemia di EBOLA è stato istituito nel 2017 il National Infection Prevention and Control Action Plan (IPC)6 in collaborazione con il CDC di Atlanta.

OBIETTIVI DEL PROGETTO

Avviare una campagna di vaccinazione partendo con un progetto pilota che miri a immunizzare 500.000 persone su un target di circa 5 milioni; vaccinare quindi almeno il 10% della popolazione vaccinabile della Sierra Leone entro la primavera 2022.

FASE	ATTIVITÀ	TEMPISTICHE
FASE -1	Definizione accordi e protocolli istituzionali e diplomatici	30 ottobre
FASE 0	Missione in Sierra Leone per completamento dello studio di fattibilità	30 ottobre - 10 novembre
FASE 1	Progetto pilota su un campione limitato per fine tuning modello operativo	15 dicembre -15 gennaio
FASE 2	Avvio fase a regime con obiettivo di immunizzare almeno 500.000 persone in località definite (in primis Freetown)	15 gennaio - 15 aprile
FASE 3	Eventuale espansione della progettualità sulla base della disponibilità dei vaccini e della logistica	dal 15 aprile

COSTI STIMATI

I costi stimati per l'avvio del progetto sono stimati in **€ 250.000**, di cui al piano economico allegato al presente documento.

Tali costi sono riferibili:

- per le prime fasi: invio del team – operatori sanitari, esperti in logistica e coordinatore – in Sierra Leone per la verifica della fattibilità del progetto; una missione a Bruxelles per il coinvolgimento della Commissione Europea;
- per le fasi successive: avvio e realizzazione del progetto pilota, con l'invio del team sanitario – logistico, e delle attrezzature e dispositivi necessari alla buona riuscita della campagna vaccinale.

Le spese per l'approvvigionamento e il trasporto dei vaccini anti Covid-19 sono a carico della Struttura Commissariale.

In seguito alle prime missioni sarà possibile definire con maggiore precisione i costi complessivi per la completa realizzazione del progetto pilota.

Dopo l'adozione del primo provvedimento della Giunta Regionale Lombarda, potrebbe essere utile e opportuno avviare una attività di *fundraising* a sostegno del progetto stesso.

Preme comunque sottolineare che l'iniziativa umanitaria della Regione Lombardia si pone l'obiettivo di lavorare in modo coordinato con le iniziative internazionali di supporto alla cooperazione della Commissione Europea ed in particolare con la DG Echo, all'interno del ERCC (European Commission Union Mechanism) e UCPM (EU Civil Protection Mechanism) definendo insieme sinergie operative anche per finanziare l'operazione, volte soprattutto alla copertura dei costi della logistica e dei trasporti dei vaccini, oltre che verificare l'eventuale partecipazione finanziaria complessiva all'iniziativa.

Il piano economico, nel limite del budget sopra indicato, potrà essere rimodulato in esito alle attività di *scouting* che verranno effettuate in Sierra Leone.

PIANO ECONOMICO		
SOGGETTO PROPONENTE	AREU (COORDINAMENTO OPERATIVO UNITA' VACCINALE)	
TITOLO PROGETTO	SIERRA LEONE VACCINAZIONI ANTI COVID-19	
AREA DI SPESA	ANNO 2021	ANNO 2022
COSTI DEL PERSONALE (es. retribuzioni, collaborazioni, incarichi libero professionali ...)	€ 5.000,00	€ 15.000,00
SPESE VIAGGIO, VITTO, ALLOGGIO E TRASFERTE	€ 15.000,00	€ 20.000,00
ACQUISTO ATTREZZATURE (es. dispositivi e presidi sanitari, frigoriferi per conservazione vaccini ...)	€ 50.000,00	€ 75.000,00
COSTI DI GESTIONE (es. materiali sanitari e di consumo, dispositivi di protezione individuale ...)	€ 10.000,00	€ 20.000,00
SPESE GENERALI E CORRENTI FUNZIONAMENTO PROGETTO (es. spese generali forfettarie, logistica, spese varie, assicurazioni ...)	€ 20.000,00	€ 20.000,00
SUB-TOTALE	€ 100.000,00	€ 150.000,00
TOTALE COMPLESSIVO	€ 250.000,00	

Figure 1: Acceptance rates overall and broken down by respondent characteristics

If a COVID-19 vaccine becomes available in [country], would you take it?



COVID-19 Vaccine Acceptance and Hesitancy in Low and Middle Income Countries, and Implications for Messaging

Julio S. Solís Arce, BA^{*1}, Shana S. Warren, PhD^{*2}, Niccoló F. Meriggi, MSc^{*3}, Alexandra Scacco, PhD^{*1}, Nina McMurry, PhD^{*1}, Maarten Voors, PhD^{*4}, Georgiy Syunyaev, MPhil^{*1,5,24}, Aryn Abdul Malik, PhD^{*6}, Samya Aboutajdine, MA³, Alex Armand, PhD⁷, Saher Asad, PhD⁸, Britta Augsburg, PhD⁹, Antonella Bancalari, PhD¹⁰, Martina Björkman Nyqvist, PhD¹¹, Ekaterina Borisova, PhD^{5,12}, Constantin Manuel Bosancianu, PhD¹, Ali Cheema, PhD^{8,13}, Elliott Collins, PhD², Ahsan Zia Farooqi, MA¹³, Mattia Fracchia, MA⁷, Andrea Guariso, PhD¹⁴, Ali Hasanain, PhD⁸, Anthony Kamwesigye, BSc², Sarah Kreps, PhD¹⁵, Madison Levine, MSc⁴, Rebecca Littman, PhD¹⁶, Melina Platas, PhD¹⁷, Vasudha Ramakrishna, MSc¹⁸, Jacob N. Shapiro, PhD¹⁹, Jakob Svensson, PhD²⁰, Corey Vernot, BS¹⁸, Pedro C. Vicente, PhD⁷, Laurin B Weissinger, DPhil²¹, Baobao Zhang, PhD¹⁵, Dean Karlan, PhD^{†2,22}, Michael Callen, PhD^{‡3,23}, Matthieu Teachout, PhD^{‡3}, Macartan Humphreys, PhD^{†1,24}, Saad B. Omer, PhD^{‡6}, and Ahmed Mushfiq Mobarak, PhD^{§25}

¹WZB Berlin Social Science Center

²Innovations for Poverty Action (IPA)

³International Growth Centre (IGC)

⁴Wageningen University & Research

⁵International Center for the Study of Institutions and Development, HSE University

⁶Yale Institute for Global Health

⁷Nova School of Business and Economics

⁸Lahore University of Management Sciences

⁹The Institute for Fiscal Studies

¹⁰University of St. Andrews & The Institute for Fiscal Studies

¹¹Stockholm School of Economics and Misum

¹²Department of Economics, Ghent University

¹³Institute of Development and Economic Alternatives

¹⁴Trinity College Dublin

¹⁵Cornell University

¹⁶University of Illinois Chicago

¹⁷NYU Abu Dhabi

¹⁸Yale Research Initiative on Innovation and Scale (Y-RISE)

¹⁹Princeton University

²⁰Institute for International Economic Studies (IIES), Stockholm University

²¹Tufts University

²²Kellogg School of Management at Northwestern University

²³London School of Economics

²⁴Columbia University

²⁵Yale University

*First author.

†Last author.

‡Corresponding author. 1 Church Street, New Haven, CT 06510. Phone 203 432 3656. Email saad.omer@yale.edu

§Corresponding author. 165 Whitney Avenue, New Haven, CT 06520-8200. Phone 203 432 5787. Email ahmed.mobarak@yale.edu

Abstract

We analyze COVID-19 vaccine acceptance across 15 survey samples covering ten low- and middle-income countries (LMICs) in Asia, Africa, and South America, Russia (an upper-middle-income country), and the United States, using survey responses from 44,260 individuals. We find considerably higher willingness to take a COVID-19 vaccine in LMIC samples (80% on average) compared to the United States (65%) and Russia (30%). Vaccine acceptance was primarily explained by an interest in personal protection against COVID-19, while concern about side effects was the most commonly expressed reason for reluctance. Health workers were the most trusted sources of information about COVID-19 vaccines. Our findings suggest that prioritizing vaccine distribution to LMICs should yield high returns in promoting global immunization coverage, and that vaccination campaigns in these countries should focus on translating acceptance into uptake. Messaging highlighting vaccine efficacy and safety, delivered by healthcare workers, may be most effective in addressing remaining hesitancy.

A safe and effective vaccine against COVID-19 is a critical tool to control the pandemic. As of April 27, 2021, 22 vaccines had advanced to Stage 3 clinical trials¹ and more than a dozen vaccines had been approved in multiple countries². For example, as of April 27, 2021, Comirnaty (BioNTech/Pfizer) had been approved in more than 80 countries, while the AstraZeneca vaccine had the most country authorizations at 92.² At present, however, global vaccine distribution remains highly unequal, with much of the current supply directed toward high-income countries.³

While effective and equitable distribution of COVID-19 vaccines is a key policy priority, ensuring the population's acceptance is equally important. Trust in vaccines and the institutions that administer them are key determinants of the success of any vaccination campaign.⁴ Several studies have investigated willingness to take a potential COVID-19 vaccine in high-income countries,^{5–10} and some studies have included middle-income countries.^{3,11} Less is known, however, about vaccine acceptance in low-income countries where large-scale vaccination has yet to begin. Understanding the drivers of COVID-19 vaccine acceptance is of global concern, since a lag in vaccination in any country may result in the emergence and spread of new variants that can overcome vaccine- and prior disease-conferred immunity.^{12,13}

Our study complements the emerging global picture of COVID-19 vaccine acceptance by focusing primarily on lower income countries. We construct a sample of low- and middle-income countries (LMICs) with wide geographic coverage across Africa, Asia and Latin America. We move beyond documenting vaccine acceptance rates and analyze data on the reasons for acceptance and hesitancy, which is critical for informing the design of effective vaccine distribution and messaging.

Acceptance of childhood vaccination for common diseases—such as measles (MCV), Bacille Calmette-Guérin (BCG) and diphtheria, tetanus, and pertussis (DTP)—is generally high in LMICs, providing cause for optimism about the prospects for COVID-19 vaccine uptake. Table 1 summarizes general vaccine acceptance and coverage rates of childhood vaccines in 2018, prior to the current pandemic, for the countries included in our study. Agreement on the importance of childhood vaccinations is markedly higher in these LMICs compared to Russia and the United States. Still, existing studies on COVID-19 vaccine acceptance document substantial variation, both across and within countries, including in settings with high background levels of other vaccinations.^{3,4,11}

This literature cites concerns about COVID-19 vaccine safety, including concerns about the rapid pace of vaccine development, as reasons for hesitancy in higher-income settings,^{3,5} but other reasons may feature more prominently in LMICs. For instance, reported COVID-19 mortality rates have been consistently lower in LMICs relative to higher income countries.¹⁴ If individuals feel the risk of disease is less serious, they may be less willing to accept any perceived risks of vaccination.¹⁵ Previous studies of healthcare utilization in LMICs have also highlighted factors such as healthcare quality concerns,¹⁶ negative historical experiences involving foreign actors,^{17,18} weak support from traditional leaders,¹⁹ and mistrust in government²⁰ as barriers to uptake, which could apply to COVID-19 vaccination as well.

To promote vaccination against COVID-19 and develop effective messaging strategies, we need to know whether people are willing to take COVID-19 vaccines, the reasons why they are willing or unwilling to do so, and the most trusted sources in their decision-making. Our study investigates these questions using a common set of survey items deployed across 13 studies in Africa, South Asia, and Latin America: seven in low-income countries (Burkina Faso, Mozambique, Rwanda, Sierra Leone, Uganda), five in lower-middle-income countries (India, Nepal, Nigeria, Pakistan),

and one in an upper-middle-income country (Colombia). We compare these findings to those from two countries at the forefront of vaccine research and development, Russia and the United States. To select studies to include in our sample, we conducted an internal search within Innovations for Poverty Action (IPA), the International Growth Center (IGC), and the Berlin Social Science Center (WZB) for projects with plans to collect survey data in the second half of 2020. Study PIs agreed to include a set of common questions about COVID-19 vaccine attitudes. This strategy was guided by the need to collect information quickly and cost effectively using a survey modality (phone) that was both safe given pandemic conditions and appropriate for contexts with limited internet coverage. The final set of samples included in our study therefore reflects populations that fall under the current research priorities at IGC, IPA and WZB and, in the case of IPA and IGC, donors that prioritize working in the Global South.

Results

Our main results are shown in Figure 1 and reproduced as Appendix A Table 4. The first column provides overall acceptance rates in each study, while the remaining columns disaggregate acceptance rates by respondent characteristics. The “All LMICs” row reports averages for LMIC countries and excludes Russia and the USA.

We document meaningful variation in vaccine acceptance across and within LMICs, but generally high levels of acceptance in LMICs overall. The average acceptance rate across studies was 80.3% (95% CI 74.9–85.6%), with a median of 78, a range of 30.1 percent points and an interquartile range of 9.7. Our estimate of τ^2 is 0.007 which implies a standard deviation over country averages of 0.084.

The acceptance rate in every LMIC sample was higher than in the USA (64.6%, 61.8–67.3%) and Russia (30.4%, 29.1–31.7%). Reported acceptance was lowest in Burkina Faso (66.5% 63.5–69.5%) and Pakistan 2 (66.5%, 64.1–68.9%). The case of Pakistan may be linked to negative historical experiences with foreign-led vaccination campaigns.^{21,22} This hesitancy may be particularly problematic, given the magnitude of the second wave in neighboring India just as vaccines are becoming available, with accelerating cases in Bangladesh, Pakistan and India threatening to overwhelm health infrastructure.

We find limited evidence of variation across demographic subgroups in our LMIC samples, as shown in Appendix A Table 9. Women were generally less willing to accept the vaccine (average difference about 4.2 points, significant at $p < .01$). Respondents under age 24 and less educated respondents were marginally more willing to take the vaccine, but these differences were not statistically significant. The acceptance advantage among the less educated was most pronounced in Rwanda, Burkina Faso, and Uganda, and stands in contrast to the USA, where more educated respondents were significantly more willing to be vaccinated.

To better understand the reasoning behind vaccine acceptance, we asked those who were willing to take the vaccine why they would take it. We summarize these results in Table 3, with additional details in Appendix A Table 5. The reason most commonly given for vaccine acceptance across samples was personal protection against COVID-19 infection. The average across the LMIC samples was 91% (86–96%). In every individual study, this ranked as the most popular reason. In

distant second place among LMIC respondents was family protection with an average of 36% (28–43%). In comparison to protecting oneself and one's family, protecting one's community did not feature prominently among stated reasons for acceptance. These reasons do not vary substantially by age group, as shown in Table 11. Self-protection also ranked as the most common reason for taking the vaccine in Russia (76%, 74–78%) and the USA (94%, 92–95%).

Figure 2 summarizes the reasons given by respondents who said they were not willing to take a COVID-19 vaccine. Concern about side effects was the most frequently expressed reason for reluctance in our LMIC samples. This concern was particularly evident among African country samples. In studies Uganda 1 (85.1% 80.7–89.6%), Sierra Leone 2 (57.9%, 50.1–65.7%), Sierra Leone 1 (53.5% 47.1–59.9%) and Uganda 2 (47.3% 42.2–52.5%), more than half of respondents unwilling to take the vaccine cited worries about side effects. Respondents in Russia (36.8%, 35.2–38.4%) and even more in the USA (79.3%, 74.6–84%), frequently reported this same concern.

Study samples Uganda 2 (31%, 25.9–36.2%), Mozambique (29.7%, 18.6–40.8%) and Pakistan 1 (26%, 18–34%) showed relatively high levels of skepticism about vaccine effectiveness among hesitant respondents. This was also true in Russia (29.6%, 28.1–31.1%) and the USA (46.8%, 41–52.6%). In addition, hesitant respondents listed lack of concern about COVID-19 infection as a reason not to be vaccinated. Study samples USA (39.3% 33.5–45%), Pakistan 1 (29.4%, 20.9–37.9%) and Nepal (20.4% 6.7–34.1%) reported high rates of this answer among hesitant respondents.

In Figure 3 we report respondents' most trusted source of guidance when deciding whether to take a COVID-19 vaccine. Results from Figure 3 are reproduced as Appendix A Table 8. Appendix B Table 15 presents a complete description of response recoding from individual studies.

We find striking consistency in most trusted sources across studies. In all but one sample, including those from Russia and the USA, respondents identified the health system as the most trustworthy source to help them decide whether to take the COVID-19 vaccine. The average across LMICs was 48.1% (31.6–64.5%). Respondents in Sierra Leone 2 (89.3%, 87.2–91.5%), Nigeria (58%, 55.7–60.2%) and Burkina Faso (51.6%, 48.5–54.8%) cited health workers most often. Sierra Leone had the highest trust in health workers and the Ministry of Health, potentially due to investments in public health following the 2014-2015 Ebola epidemic.²³

The next most cited sources were family and/or friends in Colombia (36.6%, 33.5–39.7%), Nepal (35.6%, 32.9–38.3%), Russia (28.1%, 26.8–29.3%) and Burkina Faso (18.4%, 16–20.9%). Across the pooled samples, women were 3 percentage points more likely to rely on family and friends than male respondents, though this difference was not statistically significant (Figure 5 in Appendix D).

By contrast, in Sierra Leone 1 (32.5%, 29.7–35.4%), Uganda 2 (32.4%, 29.9–35%), USA (29.7%, 27–32.3%) and Nigeria (18%, 16.2–19.8%), government was the second most frequently cited. Religious leaders and celebrities were not seen as the top sources of guidance by many respondents in any sample other than Nepal, where many respondents most trusted famous people (16.1%, 13.3–18.9%).

Finally, we highlight two idiosyncratic, yet frequently mentioned, trusted sources of information in deciding whether to take a COVID-19 vaccine. In Rwanda, 34% of respondents would most trust “themselves” for guidance, the most frequent response in this sample. In the USA, 14% of respondents cited Joe Biden, then president-elect and therefore excluded from the “government”

category, as their most trusted source.

Discussion

To our knowledge, this is the first study focusing on COVID-19 vaccine attitudes in a large set of low-income and lower-middle-income countries. Our findings showed variable but broadly high levels of prospective COVID-19 vaccine acceptance across LMICs, using data from 44,260 respondents in 13 studies in ten LMICs in Africa, South Asia, and Latin America. Acceptance across these LMIC samples averaged 80.3%, ranging between 66.5% and 96.6%. The two benchmark countries, Russia and the USA, demonstrated lower COVID-19 vaccine acceptance, consistent with relatively lower pre-pandemic vaccine confidence.

Many metrics and indices measure vaccine acceptance and hesitancy globally.^{24–26,27} Our surveys used measures employed in other COVID-19 vaccine acceptance studies^{3,6–11} and recommended by the WHO Data for Action guidance,²⁸ allowing for meaningful cross-study and cross-country comparisons. We measure trust in sources of information about COVID-19 vaccination using a measure similar to that used in the Vaccine Confidence Index (VCI), a widely used survey tool.⁴

Consistent with other studies, we find higher vaccine acceptance among men than women.^{3,7–10} In contrast to studies focused primarily on higher-income countries, we find no consistently significant differences with respect to age^{7,9} or education in our LMIC samples.

A key contribution of our study relative to the previous literature is its focus on the reasons why respondents express intentions to take (or refuse) a COVID-19 vaccine. Other work has highlighted appeals to altruistic behavior or other prosocial motivations to promote vaccine acceptance.²⁹ Yet we find that the potential risks and benefits to personal well-being feature much more prominently in our respondents' reasoning, suggesting that appeals about personal protection may be more effective in LMICs.

The most commonly stated reason for vaccine refusal was concern about safety (side effects). Around 86% of our surveys were conducted as reports from Phase 2 and 3 clinical trial data were emerging for the earliest commercially available vaccines, but prior to the first Emergency Use Authorization of any vaccine (Pfizer-BioNTech approved by the USA on December 11, 2020). Early trial data showed that severe adverse effects were extremely rare,^{30–35} occurring in fewer than 10% of people in clinical trials.³⁶ Our respondents' outsized concern about side effects could reflect the rapid pace of vaccine development,³⁷ and limited information available about potential COVID-19 vaccine safety at the time of data collection. These concerns could also reflect worries about mild, yet common and transient side effects, such as fatigue, muscle pain, joint pain and headache.

Prominent media coverage of adverse events may exacerbate concerns about side effects.³⁸ In particular, new information about rare but severe cases of thrombosis associated with the Astra-Zeneca vaccine that appeared after our data collection period could affect hesitancy levels. This is of particular relevance to LMICs, which are likely to rely on the Astra-Zeneca vaccine in their immunization campaigns, through initiatives such as COVAX.

Concerns about vaccine efficacy, averaging approximately 19.2% in the LMIC samples, may also reflect a lack of information about vaccines at the time of our surveys. Strikingly, even in

low-information environments, respondents in our samples rarely cited conspiracy theories about ulterior motives on the part of corporations, politicians or the pharmaceutical industry, despite widespread popular fears about these issues in higher-income countries.³⁹

An important limitation of our study is that our samples are not fully nationally representative. Phone surveys, while necessary during a global pandemic, do not include individuals who reside outside coverage areas, lack access to a cell phone, or do not respond to calls. In addition, as shown in Table 2, several studies focus on sub-populations of interest in pre-existing studies to which questions about COVID-19 vaccination were added. Particular care should be taken in any attempt to extrapolate to the national population level from these samples. Furthermore, we emphasize that our data are not representative of all LMICs. They represent a convenience sample of studies in countries in which our organizations could quickly mobilize coordinated data collection.

The expressed intentions to take a COVID-19 vaccine that we document in our LMIC samples, if translated into behavior, would meet or exceed the current herd immunity threshold for COVID-19 (estimated at 60-80%, based on the predominant variant in circulation in these countries).⁴⁰⁻⁴² However, reported intent may not always convert vaccine uptake.⁴³ The high salience of COVID-19 due to extensive media coverage may have increased reported intentions. Conversely, reports about side effects and risks associated with expedited vaccine development may have increased hesitancy. The fast-moving pandemic and vaccine development context may change perceptions about vaccines by the time they are widely available in LMICs.

Indeed, previous research on vaccine hesitancy has emphasized how concerns that arise surrounding vaccination campaigns are often case- and context-specific,⁴⁴ making it difficult to predict exactly how COVID-19 vaccines will be received in any given setting. The lower COVID-19 vaccine acceptance rates we observe in Russia and the USA, for example, may reflect the politicization of this specific pandemic and vaccine development,⁴⁵⁻⁴⁸ in addition to generally greater vaccine skepticism.

Nonetheless, our findings suggest several concrete implications for policy relating to vaccine roll-out in LMICs. First and foremost, we document high levels of COVID-19 vaccine acceptance in LMICs compared to Russia and the USA. While global vaccine distribution has skewed heavily toward higher-income countries to date,³ our findings suggest that prioritizing distribution to LMICs is justified not only on equity grounds, but on the expectation of “better value” in maximizing global coverage more quickly.

Our findings also imply that, once vaccine distribution to LMICs begins in earnest, interventions should focus on converting positive intentions into action. Straightforward, low-cost nudges may be particularly effective in this regard. Two recent large-scale studies in the USA found that vaccination appointment reminder messages from healthcare providers increased influenza vaccine uptake.^{49,50} Similar interventions have proven effective in increasing immunization in LMIC contexts. In Ghana and Kenya, vaccination reminders plus small cash incentives increased childhood immunization coverage.^{51,52} Cash and in-kind incentives programs were also effective in Nigeria and India.^{53,54}

This recommendation is consistent with accepted frameworks, such as the WHO’s Behavioral and Social Drivers of vaccination (BeSD) model, which suggests leveraging favorable intentions through reminders and primes, and reducing access barriers when the vast majority of people

intend to be vaccinated.^{28,55} Particularly since COVID-19 vaccination may be more collectively than individually optimal, ease of access is critical to achieve high coverage.⁵⁶

Our findings also suggest directions for the design and delivery of messaging to boost COVID-19 vaccine acceptance and uptake in LMICs. We highlight four potential implications. First, our data strongly support the view that respondents from LMICs prefer to follow the guidance of actors with the most relevant knowledge and expertise. We find high levels of trust in health workers, which suggests that social and behavioral change communication (SBCC) strategies engaging local health workers may be particularly effective in encouraging efficient and comprehensive vaccine uptake and combating remaining hesitancy.^{46,57} Health workers have been the first group to receive the COVID-19 vaccine and are therefore best-positioned to share locally credible experiences of vaccination.⁵⁸ While celebrities were not identified as a particularly trustworthy source for COVID-19 advice in our study, celebrity endorsements have proven effective in other contexts and may complement a strategy that primarily focuses on health workers.⁵⁹

Second, our findings offer guidance on the specific content of vaccine messaging that is likely to be most persuasive. Hesitant respondents were most concerned about side effects and vaccine efficacy. This suggests that messaging should highlight the high efficacy rates of the COVID-19 vaccines currently on the market in reducing or eliminating disease, hospitalizations, and death, and communicate accurate information about potential side effects. Our data also suggest that messaging should emphasize the direct protective benefits of the vaccine to the adopter, since personal protection, rather than broader concerns about protecting public health, was the top reason expressed for vaccine-acceptance by our respondents.

Third, consistent with previous studies on COVID-19 vaccination^{3,7-10} our study finds lower vaccine acceptance among women than men, suggesting that messaging strategies should focus on women. Recent work in Latin America on COVID-19 vaccine messaging found that the provision of basic information about the vaccines was particularly effective in persuading hesitant women.⁶⁰

Finally, high coverage rates of existing vaccines, coupled with respondents' reliance on friends and family as information sources, suggest that the general pro-vaccination stance of many LMIC citizens could be leveraged to increase uptake of COVID-19 vaccines as they become available. Social learning strategies and norm-setting are powerful drivers of behavior in many related sectors.⁶¹ Social signaling of positive attitudes toward and uptake of COVID-19 vaccines may also help shift social norms toward even greater immunization acceptance and two-dose completion in the community at large.⁶²

Methods

Survey questions and sample construction

Survey data were collected between June 2020 and January 2021. Our main outcome measure is vaccine acceptance. Across studies, we asked respondents, "If a COVID-19 vaccine becomes available in [your country], would you take it?". This measure aligns with widely reported COVID-19 vaccine acceptance measures.^{3,6-11} If the respondent answered yes to this question, we followed up with the question, "Why would you take it? [the COVID-19 vaccine]". If the respondent said

they would not be willing to take the vaccine, we followed up with the question, “Why would you not take it? [the COVID-19 vaccine]”. Finally, regardless of their expressed willingness to take the vaccine, we asked about actors and institutions that would be most influential in their decision: “Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?” following.⁴ To examine heterogeneity across demographic strata, we collected information about gender, age, and education. Slight variations in question wording and answer options across studies are documented in [Appendix B](#).

Studies vary in terms of geographic scope, sampling methodology, and survey modality. Seven were national or nearly-national in scope. Studies from Burkina Faso, Colombia, Rwanda, and Sierra Leone (“Sierra Leone 1”) used nationally-representative samples of active mobile phone numbers reached through Random Digit Dialing (RDD). Studies in the USA and Russia were conducted online using quota samples obtained from private survey companies.

The remaining eight studies targeted sub-national populations. One study from Pakistan (“Pakistan 2”) used RDD in Punjab province. Respondents in Mozambique, Nigeria, Pakistan (“Pakistan 1”), Uganda (“Uganda 1”, “Uganda 2”), India, Nepal and Sierra Leone (“Sierra Leone 2”) were drawn from pre-existing studies to which COVID-19 vaccine questions were subsequently added. For example, Sierra Leone 2 has national coverage from a study on access to electricity and Uganda 1 sampled female caregivers of households in rural and semi-rural villages as part of a large ongoing cluster-RCT implemented across 13 districts.

Table 2 in [Appendix A](#) summarizes the geographic scope, sampling methodologies and survey modalities of all 15 studies. A detailed description of each study is included in [Appendix C](#).

All surveys were conducted remotely to minimize in-person contact and comply with social distancing guidelines. Interviews were conducted by local staff in each country in local language(s). Surveying by phone made rapid, large-scale data collection possible. In two samples, the USA and Russia, surveys occurred via online polling. All surveys lasted approximately 15 to 40 minutes.

Taken together, we have data from 20,176 individuals from 10 LMICs and 24,084 from the USA and Russia, for a total of 44,260 respondents.

Statistical Analysis

Vaccine acceptance was defined as the percentage of respondents who answered “yes” to the question, “If a COVID-19 vaccine becomes available in [country], would you take it?”. This was calculated combining all other answer options (“No”, “Don’t Know” and “Refuse”) into a single reference category. We estimated average acceptance for each individual sample via ordinary least squares (OLS) weighted by respective study population weights and robust standard errors clustered at the level relevant for the sample.

In addition to study-level estimates, we combined data from all studies other than the USA and Russia to calculate an aggregate “All LMIC studies” estimate. For these analyses, we estimated average acceptance by OLS with weights for each study normalized such that the total weight given to observations was constant across studies. Robust standard errors for these analyses were clustered at the study level.

We note the core results would be virtually unchanged at 80.8% (74.5–87.1) rather than 80.3% (74.9–85.6) using countries rather than studies as groups in the pooled analysis, that is if we set weights so that the sum of weights in each country (rather than in each study) sum to a constant and cluster standard errors at the country level (rather than the study level).

In this combined analysis, we also estimated the underlying heterogeneity of vaccine acceptance across studies using the between studies variance estimator τ^2 from a random effects model.

We conducted subgroup analyses by gender, age and education level and reported differences between groups. For age, we selected cut-offs below 25, between age 25 and 54, and above 55 years old, closely following the age breakdown proposed by recent work on COVID-19 vaccine acceptance.¹¹ However, the lower life expectancy (63 years on average)⁶³ and younger-skewing populations (only 5% of the population is above 65 years old)⁶⁴ of low-income countries in particular, precluded further disaggregation at the upper end of the age distribution. For education, we divided the sample between respondents who had completed secondary school and those that had not. We defined these two groups to reflect broader schooling trends in LMICs, where out of every 100 students entering primary education, 61% complete lower secondary education.⁶⁵ The subgroup analyses estimates are calculated in exactly the same way as the overall acceptance rate—with weights again normalized to sum to a constant within each study—with the exception that the subsample used in the analysis is limited to those respondents fitting each demographic group.

We then investigated stated reasons for COVID-19 vaccine acceptance and hesitancy, and the types of actors respondents would trust most when making the decision about whether to take a COVID-19 vaccine. We report estimates of agreement with reasons for vaccine acceptance/hesitancy and trust in actors for individual studies and for the “All LMICs” group, which includes all study samples except Russia and the USA. Estimates were calculated with the same procedure as above, varying only the quantity of interest; i.e. one model is run for each reason why a respondent would (or would not) take the vaccine and each trusted actor.

Data Availability Statement

Individual participant data (de-identified) that underlie the results reported in this article, are available without restrictions at https://github.com/wzb-ipi/covid_vaccines_nmed.

Code Availability

All code has been deposited into the publicly available GitHub repository at https://github.com/wzb-ipi/covid_vaccines_nmed. The code and output for all analyses can be easily inspected at https://wzb-ipi.github.io/covid_vaccines_nmed/replication.html.

Acknowledgements

This work would not have been possible without the hard work and ingenuity of many. For valuable contributions to data collection during the challenging context of the global pandemic, we would like to thank:

Burkina Faso: Béchir Wendemi Ouédraogo (M&E Associate), Achille Mignondo Tchibozo (Research Manager) and Touba Bakary Pare (Senior Field Manager) at IPA Burkina Faso in Ouagadougou for their work on the RECOVR (Research for Effective Covid Response) survey from which the questions used in this study were drawn.

Colombia: Margarita Rosa Cabra Gacia (Senior Research Associate), Laura Polanco, María Juliana Otálora (Research Analyst), Sofía Jaramillo (Research Manager) and Mery Galindo (Field Coordinator) at IPA Colombia in Bogotá for their work on the RECOVR (Research for Effective Covid Response) survey from which the questions used in this study were drawn.

India: Bhartendu Trivedi, Yashashvi Singh, Tatheer Fatima and the field team of Morsel Research and Development.

Mozambique: Alberto Arlindo, Imamo Mussa, Ismail Mussa, Frederica Mendonça and Simão Paiva from NOVAFRICA Mozambique office.

Nepal: Arjun Kharel and field staff at the Centre for the Study of Labour and Mobility (CESLAM) in Kathmandu.

Nigeria: Opeyemi Adejo (Department of Sociology, University of Lagos), Deborah Anigo, Isaac Obara, Segun Fayomi, and Aishwarya Kumar at the Busara Center for Behavioral Economics, and Sarah Ryan (University of Illinois at Chicago) for research assistance.

Pakistan 1: Ahsan Tariq and Shan e Muhammad Malik at the Institute for Development and Economic Alternatives (IDEAS) in Lahore as survey wing leads and Hamid Ali Tiwana for research assistance.

Pakistan 2: Staff and the internal survey firm at the Centre for Economic Research Pakistan (CERP).

Rwanda: Jean Leodomir Habarimana Mfura (Research and Policy Coordinator), Jean Aime Ns-abimana and Gisele Manirabaruta (Field Manager) at IPA Rwanda in Kigali for their work on the RECOVER (Research for Effective Covid Response) survey from which the questions used in this study were drawn.

Russia: Staff at Online Market Intelligence Survey Agency, Kirill Chmel (HSE University) and Vladimir Zabolotsky (HSE University and University of Bologna) for their intellectual contributions and research assistance.

Sierra Leone 1: Filippo Cuccaro (Research Coordinator) and Fatoma Momoh (Senior Field Manager) at IPA Sierra Leone in Freetown for their work on the RECOVER (Research for Effective Covid Response) survey from which the questions used in this study were drawn.

Sierra Leone 2: Sellu Kallon (Field Manager), Junisa Nabieu (Field Supervisor), Momoh Flee (Field Supervisor), Hamid Kai, Mohamed Lamin (Field Supervisor) and all enumerators at IGC-Sierra Leone Freetown office and Wageningen University's Project "Tracking the Economic Consequences of COVID-19 in Sierra Leone".

Uganda 1: Staff at IPA Uganda, especially Sarene Shaked and Gloria Ayesiga, for their intellectual contributions, research assistance, and support throughout the Uganda 1 study.

Uganda 2: Co-PIs Ana Garcia Hernandez, Leah Rosenzweig, Lily Tsai, and Elly Atuhumuza, Martin Atyera, and their team of survey enumerators and support staff at IPA Uganda.

United States: Staff at Lucid (survey firm) for distributing the survey and providing the online survey sample.

IGC thanks their resident country teams in Sierra Leone, Uganda, Pakistan, and Mozambique for their continued guidance, coordination of activities with researchers and direct engagement and dissemination activities with national policymakers:

- Herbert McLeod (Country Director) and Abou Bakarr Kamara (Country Economist) at IGC Sierra Leone
- Richard Newfarmer (Country Director), Priya Manwaring (Country Economist), and Jakob Rauschendorfer (Country Economist) at IGC - Uganda
- Ijaz Nabi (Country Director), Hina Shaikh (Country Economist), and Usman Naeem (Country Economist) at IGC - Pakistan
- Claudio Frischtak (Country Director) and Egas Daniel (Country Economist) at IGC - Mozambique

IPA thanks staff from its global offices for their research assistance and support throughout the RECOVER survey. Hugo Salas (IPA Mexico) contributed to data analysis for Burkina Faso, Rwanda and Sierra Leone. Margarita Rosa Cabra Garcia also contributed to data analysis for Colombia. At IPA New York and Washington, DC, Michael Rosenbaum and Savanna Henderson provided research assistance.

NOVAFRICA thanks Cátia Batista (NOVA SBE), Sandra Sequeira (LSE) and Inês Vilela (Royal Holloway, University of London and NOVAFRICA) for their intellectual contributions.

Centre for Economic Research Pakistan (CERP) thanks Javaeria Qureshi (University of Illinois Chicago), Taimur Shah (CERP), and Basit Zafar (University of Michigan) for their contributions to the Economic Vulnerability Assessment (EVA) project from which the questions used in the Pakistan 2 study were drawn.

Contributors

JSo, SW, NMe, AS, NMc, GS, MV and AM are co-first authors. DK, MC, MT, MH, AMM and SO are co-last authors. AMM and SO are also the corresponding authors. DK, AMM, MT, NMe, MC, and MV conceived of the study and provided overall guidance. SAb and NMe led the literature search, with input from AS, NMc, SW, AMM, AM and JSo. SW, NMe, AS, NMc, MV, GS, AA, SA, BA, AB, EB, CMB, AC, EC, MF, AG, AK, SK, RL, MBN, MP, JSh, JSv, PV, LB, BZ, MC, SAs, AC, AF, AH, MC, MT, and MH oversaw data collection as part of other research efforts. SW, NMe, and MT coordinated the project across study samples. The following verified the underlying data for individual study samples: EC (Burkina Faso, Colombia, Rwanda, Sierra Leone 1), BA and AB (India), AS and RL (Nigeria), AG, JSv and MBN (Uganda 1), CMB and MH (Uganda 2), NMe and MV (Sierra Leone 2), GS (Russia), MF (Mozambique), AF and JSh (Pakistan 1), SAs (Pakistan 2), CV (Nepal), and NMc (USA). JSo, GS, MH and SA collated and processed all datasets used for the analysis. NMe, MH, AMM, JSo, GS, SW, AS, EC, EB, MT, MV and NMc did the data interpretation with guidance from SO and AM. JSo, GS, EC and MH verified final datasets and analysis. JSo and GS did the data analysis and produced output figures with input from MH, AMM, DK, SW, EC, MV, NMe and MT. MH supervised the data analysis. JSo, SW, NMe, AMM, AS, NMc and MV wrote the first draft of the manuscript, with guidance from AM and SO. JSo, SW, NMe, AS, NMc, MV, SAb, EB, MP, JSh, PV, BZ, MC, MT, MH, AMM and SO revised the manuscript. All authors approved the final version of the manuscript. All authors had full access to all the data used in this study and had final responsibility for the decision to submit for publication.

Funding

Funding was provided by Beyond Conflict, Bill and Melinda Gates Foundation, Columbia University, Givewell.org, Ghent University, HSE University Basic Research Program, International Growth Centre, Jameel Poverty Action Lab Crime and Violence Initiative, London School of Economics and Political Science, Mulago Foundation, NOVAFRICA at the Nova School of Business and Economics, NYU Abu Dhabi, Oxford Policy Management, Princeton University, Social Science Research Council, Trinity College Dublin COVID19 Response Funding, UK Aid, UKRI GCRF/Newton Fund, United Nations Office for Project Services, Weiss Family Fund, WZB Berlin Social Science Center, Yale Institute for Global Health, Yale Macmillan Center, and anonymous donors to IPA and Y-RISE.

Role of the funding source

None of our funders played any role in the collection, analysis, interpretation, writing or decision to submit this article for publication.

Declaration of interests

We declare no competing interests.

References

1. World Health Organization. Draft landscape and tracker of COVID-19 candidate vaccines. <https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines> (2021).
2. McGill COVID19 Vaccine Tracker Team. COVID-19 Vaccine Tracker. <https://covid19.trackvaccines.org/vaccines/> (2021).
3. Wouters, O. J. *et al.* Challenges in ensuring global access to COVID-19 vaccines: Production, affordability, allocation, and deployment. *The Lancet* (2021).
4. de Figueiredo, A., Simas, C., Karafillakis, E., Paterson, P. & Larson, H. J. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: A large-scale retrospective temporal modelling study. *The Lancet* **396**, 898–908 (2020).
5. Ipsos-World Economic Forum. Global attitudes: COVID-19 vaccines. <https://www.ipsos.com/en-ro/global-attitudes-covid-19-vaccine-january-2021> (2021).
6. Malik, A., McFadden, S., Elharake, J. & Omer, S. Determinants of COVID-19 vaccine acceptance in the US. *EClinicalMedicine* **26**, 100495 (2020).
7. Kreps, S. *et al.* Factors associated with US adults' likelihood of accepting COVID-19 vaccination. *JAMA Network Open* **3**, e2025594–e2025594 (2020).
8. Shekhar, R. *et al.* COVID-19 vaccine acceptance among health care workers in the United States. *Vaccines* **9**, 119 (2021).
9. Dror, A. A. *et al.* Vaccine hesitancy: the next challenge in the fight against COVID-19. *European Journal of Epidemiology* **35**, 775–779 (2020).
10. Fisher, K. A. *et al.* Attitudes toward a potential SARS-CoV-2 vaccine: a survey of US adults. *Annals of Internal Medicine* **173**, 964–973 (2020).
11. Lazarus, J. V. *et al.* A global survey of potential acceptance of a COVID-19 vaccine. *Nature medicine* **27**, 225–228 (2021).
12. Ong, S. W. X., Young, B. E. & Lye, D. C. Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes. *The Lancet Infectious Diseases* (2021).
13. The Lancet COVID-19 Commission Task Force on Public Health Measures to Suppress the Pandemic. SARS-CoV-2 variants: the need for urgent public health action beyond vaccines. <https://covid19commission.org/public-health-measures> (2021).
14. Mukherjee, S. Why does the pandemic seem to be hitting some countries harder than others? *New Yorker* (2021).
15. Brewer, N. T. *et al.* Meta-analysis of the relationship between risk perception and health behavior: The example of vaccination. *Health psychology* **26**, 136 (2007).

16. Christensen, D., Dube, O., Haushofer, J., Siddiqi, B. & Voors, M. Building Resilient Health Systems: Experimental Evidence from Sierra Leone and the 2014 Ebola Outbreak. *The Quarterly Journal of Economics* **136**, 1145–1198 (2021).
17. Lowes, S. & Montero, E. The legacy of colonial medicine in Central Africa. *American Economic Review* **111**, 1284–1314 (2021).
18. Martinez-Bravo, M. & Stegmann, A. In Vaccines We Trust? The Effects of the Cia’s Vaccine Ruse on Immunization in Pakistan. *CEPR Discussion Paper No. DP15847* (2021).
19. Jegede, A. S. What led to the Nigerian boycott of the polio vaccination campaign? *PLOS Medicine* **4**(3), (2007).
20. Blair, R., Morse, B. & Tsai, L. Public health and public trust: Survey evidence from the Ebola Virus Disease epidemic in Liberia. *Social Science & Medicine* **172**, 89–97 (2017).
21. Ali, M. *et al.* Polio vaccination controversy in pakistan. *The Lancet* **394**, 915–916 (2019).
22. Robbins, A. The CIA’s vaccination ruse. *Journal of Public Health Policy* **33**, 387–389 (2012).
23. Deserranno, E. & León-Ciliotta, G. Promotions and Productivity: The Role of Meritocracy and Pay Progression in the Public Sector. *CEPR Discussion Paper No. DP15837* (2021).
24. Betsch, C. *et al.* Beyond confidence: Development of a measure assessing the 5C psychological antecedents of vaccination. *PloS one* **13**, e0208601 (2018).
25. Domek, G. J. *et al.* Measuring vaccine hesitancy: Field testing the WHO SAGE working group on vaccine hesitancy survey tool in guatemala. *Vaccine* **36**, 5273–5281 (2018).
26. Shapiro, G. K. *et al.* The vaccine hesitancy scale: Psychometric properties and validation. *Vaccine* **36**, 660–667 (2018).
27. Gilkey, M. B. *et al.* The vaccination confidence scale: A brief measure of parents’ vaccination beliefs. *Vaccine* **32**, 6259–6265 (2014).
28. World Health Organization. Data for action: achieving high uptake of COVID-19 vaccines. <https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccination-demand-planning-2021.1> (2021).
29. Chou, W.-Y. S. & Budenz, A. Considering emotion in COVID-19 vaccine communication: Addressing vaccine hesitancy and fostering vaccine confidence. *Health communication* **35**, 1718–1722 (2020).
30. Mulligan, M. J. *et al.* Phase i/II study of COVID-19 RNA vaccine BNT162b1 in adults. *Nature* **586**, 589–593 (2020).
31. Logunov, D. Y. *et al.* Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in russia. *The Lancet* **397**, 671–681 (2021).

32. Folegatti, P. M. *et al.* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1/2, single-blind, randomised controlled trial. *The Lancet* **396**, 467–478 (2020).
33. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in brazil, south africa, and the UK. *The Lancet* **397**, 99–111 (2021).
34. Baden, L. R. *et al.* Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *New England Journal of Medicine* **384**, 403–416 (2021).
35. Polack, F. P. *et al.* Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine. *New England Journal of Medicine* **383**, 2603–2615 (2020).
36. Wadman, M. Public needs to prep for vaccine side effects. *Science* **370**, 1022–1022 (2020).
37. Callaway, E. Russia’s fast-track coronavirus vaccine draws outrage over safety. *Nature* **584**, 334–335 (2020).
38. Stein, R. A. The golden age of anti-vaccine conspiracies. *Germs* **7**, 168 (2017).
39. Loomba, S., de Figueiredo, A., Piatek, S. J., Graaf, K. de & Larson, H. J. Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA. *Nature Human Behaviour* (2021) doi:[10.1038/s41562-021-01056-1](https://doi.org/10.1038/s41562-021-01056-1).
40. Omer, S. B., Yildirim, I. & Forman, H. P. Herd immunity and implications for SARS-CoV-2 control. *Jama* **324**, 2095–2096 (2020).
41. Aschwanden, C. Five reasons why COVID herd immunity is probably impossible. *Nature* **591**, 520–522 (2021).
42. McNeil, D. G. How much herd immunity is enough? *The New York Times* (2021).
43. Mceachan, R., Conner, M., Taylor, N. & Lawton, R. Prospective prediction of health-related behaviours with the theory of planned behaviour: A meta-analysis. *Health Psychology Review* **5**, 97 (2011).
44. Larson, H. J., Cooper, L. Z., Eskola, J., Katz, S. L. & Ratzan, S. Addressing the vaccine confidence gap. *The Lancet* **378**, 526–535 (2011).
45. Hornsey, M. J., Finlayson, M., Chatwood, G. & Begeny, C. T. Donald trump and vaccination: The effect of political identity, conspiracist ideation and presidential tweets on vaccine hesitancy. *Journal of Experimental Social Psychology* **88**, 103947 (2020).
46. Bokemper, S. E., Huber, G. A., Gerber, A. S., James, E. K. & Omer, S. B. Timing of COVID-19 vaccine approval and endorsement by public figures. *Vaccine* **39**, 825–829 (2021).

47. Åslund, A. Responses to the COVID-19 crisis in russia, ukraine, and belarus. *Eurasian Geography and Economics* **61**, 532–545 (2020).
48. Burki, T. K. The russian vaccine for COVID-19. *The Lancet Respiratory Medicine* **8**, e85–e86 (2020).
49. Milkman, K. L. *et al.* A mega-study of text-based nudges encouraging patients to get vaccinated at an upcoming doctor’s appointment. (2021).
50. Milkman, K. L. *et al.* A mega-study of text-message nudges encouraging patients to get vaccinated at their pharmacy. (2021).
51. Levine, G., Salifu, A., Mohammed, I. & Fink, G. Mobile Nudges and Financial Incentives to Improve Coverage of Timely Neonatal Vaccination in Rural Areas (GEVaP trial): A 3-armed Cluster Randomized Controlled Trial in Northern Ghana. *PLOS One* (2021).
52. Gibson, D. G. *et al.* Mobile phone-delivered reminders and incentives to improve childhood immunisation coverage and timeliness in Kenya (M-SIMU): a cluster randomised controlled trial. *The Lancet Global Health* **5**, e428–e438 (2017).
53. ID Insight. Impact of conditional cash transfers on routine childhood immunizations in North West Nigeria. https://files.givewell.org/files/DWDA%202009/NewIncentives/IDInsight_Impact_Evaluation_of_New_Incentives_Final_Report.pdf (2020).
54. Banerjee, A. V., Duflo, E., Glennerster, R. & Kothari, D. Improving immunisation coverage in rural India: clustered randomised controlled evaluation of immunisation campaigns with and without incentives. *BMJ* **340**, (2010).
55. Brewer, N. T., Chapman, G. B., Rothman, A. J., Leask, J. & Kempe, A. Increasing vaccination: Putting psychological science into action. *Psychological Science in the Public Interest* **18**, 149–207 (2017).
56. Betsch, C., Böhm, R. & Korn, L. Inviting free-riders or appealing to prosocial behavior? Game-theoretical reflections on communicating herd immunity in vaccine advocacy. *Health Psychology* **32**, 978 (2013).
57. World Health Organization. Behavioural considerations for acceptance and uptake of COVID-19 vaccines: WHO technical advisory group on behavioural insights and sciences for health, meeting report, 15 October 2020. <https://apps.who.int/iris/handle/10665/337335> (2020).
58. Katzman, J. G. & Katzman, J. W. Primary care clinicians as COVID-19 vaccine ambassadors. *Journal of Primary Care & Community Health* **12**, 21501327211007026 (2021).
59. Alatas, V., Chandrasekhar, A. G., Mobius, M., Olken, B. A. & Paladines, C. When celebrities speak: A nationwide twitter experiment promoting vaccination in indonesia. *National Bureau of Economic Research* (2019).
60. Argote, P. *et al.* Messaging interventions that increase COVID-19 vaccine willingness in latin america. *SSRN 3812023* (2021).

61. Beaman, L., BenYishay, A., Magruder, J. & Mobarak, A. M. Can network theory-based targeting increase technology adoption? *National Bureau of Economic Research* (2018).
62. Karing, A. Social signaling and childhood immunization: A field experiment in sierra leone. *University of California, Berkeley Working Paper* (2018).
63. World Bank. World Development Indicators: Life expectancy at birth, total (years) - Low & middle income, Low income countries [Data file]. <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=XO-XM> (2018).
64. World Bank. World Bank staff estimates based on age/sex distributions of United Nations Population Division's World Population Prospects: 2019 Revision, Population ages 65 and above (% of total population) - Sub-Saharan Africa [Data file]. <https://data.worldbank.org/indicator/SP.POP.65UP.TO.ZS?locations=ZG> (2019).
65. Bank, W. *World development report 2018: Learning to realize education's promise*. (The World Bank, 2017).
66. The Economist Intelligence Unit. Q1 global forecast 2021 Coronavirus vaccines: expect delays. <https://www.eiu.com/n/campaigns/q1-global-forecast-2021/> (2021).
67. Centre for Disease Control and Prevention. Local Reactions, Systemic Reactions, Adverse Events, and Serious Adverse Events: Pfizer-BioNTech COVID-19 Vaccine. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html> (2020).
68. CDC COVID-19 Response Team & Food and Drug Administration. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020. <https://www.cdc.gov/mmwr/volumes/70/wr/mm7002e1.htm#:~:text=Early%20safety%20monitoring%20of%20the,nonanaphylaxis%20allergic%20reactions%2C%20based%20on> (2021).
69. Bowles, J., Larreguy, H. & Liu, S. Countering misinformation via WhatsApp: Preliminary evidence from the COVID-19 pandemic in zimbabwe. *PloS one* **15**, e0240005 (2020).

Table 1: Vaccination beliefs and coverage for the countries in our sample

	% Respondents agreeing Vaccines are...			Vaccine coverage in 2019 (% of infants)			% of parents with any child that was ever vaccinated
	Effective	Safe	Important for children to have	Tuberculosis (BCG)	Diphtheria, Tetanus and Pertussis (DTP1)	Measles (MCV1)	
Burkina Faso	87	72	95	98	95	88	97
Colombia	83	84	99	89	92	95	95
India	96	97	98	92	94	95	92
Mozambique	87	93	98	94	93	87	95
Nepal	89	93	99	96	96	92	95
Nigeria	82	92	96	67	65	54	95
Pakistan	91	92	95	88	86	75	94
Rwanda	99	97	99	98	99	96	100
Sierra Leone	95	95	99	86	95	93	97
Uganda	82	87	98	88	99	87	98
Russia	67	48	80	96	97	98	96
USA	85	73	87	.	97	90	95

Table 1 presents an overview of vaccination beliefs and incidence across countries in our sample. Columns 2-4 and 8 use data from the Wellcome Global Monitor 2018. Column 8 shows the percentage of respondents who are parents and report having had any of their children ever vaccinated. Columns 2-4 show the percentage of all respondents that either strongly agree or somewhat agree with the statement above each column. All percentages are obtained using national weights. Columns 5-7 use data from the World Health Organization on vaccine incidence. Columns 5-7 report the percentage of infants per country receiving the vaccine indicated in each column.

Table 2: Summary of studies sampling

Study	Date	Geographic scope	Sampling methodology	Survey modality	Weights
Burkina Faso	October to December 2020	National	Random digit dialing (RDD)	Phone	Yes
Colombia	August 2020	National	Random digit dialing (RDD)	Phone	Yes
India	June 2020 to January 2021	Subnational, Slums in 2 cities	Representative sample of slum dwellers living in vicinity of a community toilet and located in Uttar Pradesh	Phone	Yes
Mozambique	October to November 2020	Subnational, 2 cities	1) Random sample in urban and periurban markets stratified by gender and type of establishment in Maputo; 2) Random sample representative of communities in the Cabo Delgado, stratified on urban, semiurban, and rural areas	Phone	No
Nepal	December 2020	Subnational, 2 districts	Random sample of poor households from randomly selected villages in Kanchanpur	Phone	Yes
Nigeria	November to December 2020	Subnational, 1 state	1) Random sample of individuals in Kaduna; 2) Sample of phone numbers from a phone list of Kaduna state residents	Phone	No
Pakistan 1	July to September 2020	Subnational, 2 districts	Random sample of individuals in administrative police units in two districts of Punjab	Phone	Yes
Pakistan 2	September to October 2020	Subnational, 1 province	Random digit dialing (RDD) on a random sample of all numerically possible mobile phone numbers in the region of Punjab	Phone	No
Russia	November to December 2020	Subnational, 61 regions	Sample recruited from the Russian online survey company OMI (Online Market Intelligence). Sampling targeted at having a minimum of respondents per region, as well as representation of age, gender and education groups.	Online	Yes
Rwanda	October to November 2020	National	Random digit dialing (RDD)	Phone	Yes
Sierra Leone 1	October 2020	National	Random digit dialing (RDD)	Phone	Yes
Sierra Leone 2	October 2020 to January 2021	National	A random sample of households in 195 rural towns across all 14 districts of Sierra Leone	Phone	No
Uganda 1	September to December 2020	Subnational, 13 districts	Sample of women in households from semi-rural and rural villages across 13 districts in Uganda, selected according to the likelihood of having children	Phone	No
Uganda 2	November to December 2020	Subnational, 1 district	Random sample of households in Kampala	Phone	No
USA	December 2020	National	Nation-wide sample of adult internet users recruited through the market research firm Lucid	Online	Yes

Figure 1: Acceptance rates overall and broken down by respondent characteristics

If a COVID-19 vaccine becomes available in [country], would you take it?




Figure 1 presents average acceptance of the COVID-19 vaccine across studies and subgroups within studies. For each study, we summarize sampling information in parentheses in the following way: First, we indicate whether the geographic coverage of the sample is national or subnational. If the coverage is subnational we provide further details. Second, we list the number of observations included in the study. In the plot, points represent the estimated percentage of individuals who would take the vaccine. “No”, “Don’t know” and “Refuse” are taken as a single reference category. Bars around each point indicate a 95% confidence interval for the estimate. An estimate of average acceptance for all studies in LMICs (excluding USA and Russia) is also shown.

Table 3: Reasons to take the vaccine

Study	N	Protection		
		Self	Family	Community
Burkina Faso	651	76 (73, 79)	42 (38, 46)	7 (5, 9)
Colombia	756	91 (88, 93)	23 (20, 26)	12 (10, 14)
Mozambique	768	83 (80, 86)	32 (27, 38)	4 (2, 5)
Nepal	1341	96 (95, 98)	34 (32, 37)	20 (17, 22)
Nigeria	1424	89 (88, 91)	35 (33, 38)	21 (19, 23)
Rwanda	1152	98 (97, 99)	26 (23, 28)	11 (9, 13)
Sierra Leone 1	836	94 (92, 96)	37 (34, 40)	21 (18, 23)
Sierra Leone 2	1855	91 (88, 93)	62 (57, 66)	21 (16, 27)
Uganda 1	2885	96 (95, 97)	36 (34, 38)	9 (8, 10)
Uganda 2	1045	96 (95, 97)	28 (25, 31)	11 (9, 12)
All LMICs	.	91 (86, 96)	36 (28, 43)	14 (9, 18)
Russia	5887	76 (74, 78)	69 (67, 71)	41 (38, 43)
USA	1313	94 (92, 95)	92 (90, 94)	89 (87, 91)

Table 3 shows percentage of respondents mentioning reasons why they would take the Covid-19 vaccine. The number of observations and percentage corresponds only to people who would take the vaccine. Respondents in all countries could give more than one reason. A 95% confidence interval is shown between parentheses. Studies India, Pakistan 1 and Pakistan 2 are not included because they either did not include the question or were not properly harmonized with the other studies.

Figure 2: Reasons not to take the vaccine

Why would you not take the COVID-19 vaccine?




Figure 2 shows the percentage of respondents mentioning reasons why they would not take the COVID-19 vaccine. In the plot, points represent the estimated percentage of individuals that would not take the vaccine or do not know if they would take the vaccine for each possible response option. Bars around each point indicate a 95% confidence interval for the estimate. An estimated average for all studies in LMICs is also shown. Size of points illustrates the number of observations in each response option. Studies India and Pakistan 2 are not included because they either did not include the question or were not properly harmonized with the other studies.

Figure 3: Trusted actors and institutions, broken down by expressed willingness to take a COVID-19 vaccine

Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine?




Figure 3 shows histograms of actors and institutions respondents say they would trust most to help them decide whether to take the COVID-19 vaccine. Respondents were only permitted to select one most trusted actor or institution. Studies India, Mozambique, Pakistan 1, Pakistan 2 and Uganda 1 are not included because they either did not include the question or were not properly harmonized with the other studies.

Supplementary Appendix

Appendix A: Supplementary tables, figures and results

Table 4: If a COVID-19 vaccine becomes available in [country], would you take it? Disaggregated by subgroups

Country	Average acceptability	Gender		Education		Age		
		Female	Male	> Secondary	Up to Secondary	<25	25-54	55+
Burkina Faso	66.5 (63.5, 69.5)	62.1 (56.3, 67.9)	68.4 (65.0, 71.9)	60.8 (55.9, 65.8)	70.1 (66.4, 73.8)	76.0 (58.0, 94.0)	63.2 (53.0, 73.4)	. .
Colombia	74.9 (72.2, 77.6)	73.5 (70.1, 77.0)	77.3 (73.0, 81.7)	78.1 (73.6, 82.5)	73.4 (70.1, 76.8)	75.4 (67.5, 83.4)	74.2 (70.2, 78.3)	73.8 (65.0, 82.6)
India	84.3 (82.3, 86.3)	82.4 (79.0, 85.8)	84.7 (82.5, 87.0)	87.8 (81.1, 94.6)	85.9 (82.5, 89.2)	77.6 (71.6, 83.6)	85.4 (83.4, 87.3)	83.1 (77.6, 88.5)
Mozambique	89.1 (86.5, 91.7)	86.2 (82.5, 90.0)	91.3 (88.4, 94.1)	86.1 (81.8, 90.4)	89.7 (86.5, 92.8)	. .	88.3 (85.3, 91.2)	91.7 (88.1, 95.4)
Nepal	96.6 (95.5, 97.6)	96.4 (94.6, 98.2)	96.4 (95.1, 97.7)	. .	. .	97.8 (95.7, 99.8)	96.6 (95.2, 97.9)	93.8 (90.4, 97.2)
Nigeria	76.2 (74.3, 78.2)	74.9 (71.7, 78.1)	77.0 (74.6, 79.4)	. .	. .	69.0 (63.3, 74.7)	77.6 (75.5, 79.7)	74.7 (65.8, 83.6)
Pakistan 1	76.1 (70.0, 82.3)	72.2 (65.6, 78.8)	80.1 (73.8, 86.4)	83.6 (76.6, 90.5)	74.0 (67.4, 80.5)	86.3 (78.4, 94.1)	75.6 (69.3, 81.8)	80.8 (64.9, 96.7)
Pakistan 2	66.5 (64.1, 68.9)	. .	. .	71.4 (67.3, 75.5)	64.2 (61.2, 67.1)	. .	. .	. .
Rwanda	84.9 (82.9, 86.8)	79.4 (75.8, 83.0)	88.0 (85.8, 90.2)	71.4 (65.5, 77.2)	87.7 (85.8, 89.7)	88.1 (85.0, 91.1)	83.8 (81.3, 86.3)	73.3 (59.2, 87.3)
Sierra Leone 1	78.0 (75.5, 80.5)	74.1 (69.5, 78.7)	80.1 (77.2, 83.1)	74.4 (70.1, 78.7)	80.2 (77.0, 83.3)	78.0 (72.4, 83.6)	78.3 (75.4, 81.1)	74.0 (61.4, 86.6)
Sierra Leone 2	87.9 (86.2, 89.6)	88.6 (85.7, 91.5)	87.7 (85.9, 89.5)	88.8 (85.0, 92.5)	87.8 (86.0, 89.6)	82.9 (73.9, 91.9)	87.6 (85.6, 89.5)	90.0 (87.4, 92.6)
Uganda 1	85.8 (84.4, 87.2)	85.8 (84.4, 87.2)	. .	80.1 (74.4, 85.9)	84.8 (83.2, 86.5)	85.5 (82.7, 88.4)	85.9 (84.3, 87.4)	. .
Uganda 2	76.5 (74.3, 78.7)	74.9 (71.5, 78.3)	78.0 (75.2, 80.9)	68.6 (64.3, 72.9)	79.8 (77.3, 82.2)	76.5 (71.0, 82.1)	77.0 (74.4, 79.6)	73.7 (67.3, 80.0)
All LMICs	80.3 (74.9, 85.6)	79.2 (73.4, 85.0)	82.6 (77.4, 87.9)	77.4 (71.4, 83.4)	79.8 (74.1, 85.4)	82.8 (76.9, 88.7)	81.1 (75.6, 86.6)	79.1 (72.5, 85.7)
Russia	30.4 (29.1, 31.7)	22.6 (20.9, 24.2)	38.5 (36.5, 40.5)	31.0 (29.6, 32.5)	29.6 (27.3, 32.0)	33.5 (29.2, 37.7)	27.6 (26.2, 28.9)	40.0 (35.9, 44.0)
USA	64.6 (61.8, 67.3)	56.1 (52.1, 60.1)	73.4 (69.8, 76.9)	72.3 (69.5, 75.0)	51.5 (46.0, 57.0)	51.0 (43.5, 58.6)	64.9 (61.1, 68.7)	69.4 (64.8, 73.9)

Table 4 shows percentage of respondents willing to take the COVID-19 vaccine as plotted in Figure 1. A 95% confidence interval is shown between parentheses

Table 5: Reasons to take the vaccine- all categories

Study	N	Protection			If recommended by		
		Self	Family	Community	Health workers	Government	Other
Burkina Faso	651	76 (73, 79)	42 (38, 46)	7 (5, 9)	6 (4, 8)	19 (16, 22)	2 (1, 3)
Colombia	756	91 (88, 93)	23 (20, 26)	12 (10, 14)	1 (0, 2)	2 (1, 3)	6 (4, 7)
Mozambique	768	83 (80, 86)	32 (27, 38)	4 (2, 5)	. (0, 2)	7 (5, 8)	3 (2, 4)
Nepal	1341	96 (95, 98)	34 (32, 37)	20 (17, 22)	2 (1, 2)	3 (2, 4)	7 (5, 9)
Nigeria	1424	89 (88, 91)	35 (33, 38)	21 (19, 23)	. (0, 1)	6 (4, 7)	4 (3, 5)
Rwanda	1152	98 (97, 99)	26 (23, 28)	11 (9, 13)	1 (0, 1)	5 (4, 6)	1 (1, 2)
Sierra Leone 1	836	94 (92, 96)	37 (34, 40)	21 (18, 23)	12 (10, 14)	23 (20, 25)	7 (5, 9)
Sierra Leone 2	1855	91 (88, 93)	62 (57, 66)	21 (16, 27)	59 (54, 63)	. (0, 1)	16 (11, 21)
Uganda 1	2885	96 (95, 97)	36 (34, 38)	9 (8, 10)	. (0, 1)	10 (9, 12)	6 (5, 7)
Uganda 2	1045	96 (95, 97)	28 (25, 31)	11 (9, 12)	1 (1, 2)	15 (13, 17)	2 (1, 3)
All LMICs	.	91 (86, 96)	36 (28, 43)	14 (9, 18)	12 (-8, 31)	10 (4, 16)	5 (2, 8)
Russia	5887	76 (74, 78)	69 (67, 71)	41 (38, 43)	11 (10, 13)	6 (5, 7)	18 (16, 20)
USA	1313	94 (92, 95)	92 (90, 94)	89 (87, 91)	. (0, 1)	67 (64, 70)	. (0, 1)

Table 5 shows percentage of respondents mentioning reasons why they would take the Covid-19 vaccine. The number of observations and percentage corresponds only to people who would take the vaccine. Respondents in all countries could give more than one reason. A 95% confidence interval is shown between parentheses

Table 6: Reasons to take the vaccine- by age groups

Study	Self			Family			Community		
	<25	25-54	55+	<25	25-54	55+	<25	25-54	55+
Burkina Faso	77	59	100	26	64	66	11	2	0
Conf. interval	(56, 99)	(46, 72)	(100, 100)	(4, 48)	(51, 77)	(-80, 211)	(-5, 26)	(-2, 5)	(0, 0)
n	19	57	3	19	57	3	19	57	3
Colombia	91	91	90	26	26	16	12	13	14
Conf. interval	(86, 97)	(88, 94)	(83, 97)	(17, 35)	(21, 31)	(8, 25)	(4, 20)	(9, 16)	(6, 22)
n	90	349	73	90	349	73	90	349	73
Mozambique	62	84	80	50	32	34	12	4	2
Conf. interval	(19, 106)	(81, 87)	(75, 86)	(5, 95)	(26, 38)	(27, 41)	(-17, 42)	(2, 6)	(0, 4)
n	8	571	188	8	571	188	8	571	188
Nepal	97	97	92	31	36	27	15	20	19
Conf. interval	(94, 100)	(96, 98)	(87, 97)	(25, 37)	(33, 39)	(19, 36)	(10, 20)	(17, 23)	(13, 25)
n	225	890	162	225	890	162	225	890	162
Nigeria	91	89	94	31	36	31	22	21	21
Conf. interval	(87, 95)	(87, 91)	(89, 100)	(25, 38)	(33, 39)	(20, 42)	(16, 29)	(18, 23)	(11, 31)
n	178	1175	71	178	1175	71	178	1175	71
Rwanda	98	98	100	22	28	29	10	11	10
Conf. interval	(97, 100)	(97, 99)	(100, 100)	(17, 26)	(24, 31)	(12, 46)	(7, 13)	(9, 14)	(-1, 21)
n	389	732	31	389	732	31	389	732	31
Sierra Leone 1	96	94	94	36	38	27	24	20	22
Conf. interval	(93, 99)	(92, 95)	(86, 102)	(29, 44)	(34, 41)	(12, 42)	(17, 31)	(16, 23)	(8, 36)
n	167	632	37	167	632	37	167	632	37
Sierra Leone 2	87	90	93	52	62	62	29	22	18
Conf. interval	(78, 97)	(88, 92)	(89, 97)	(39, 66)	(58, 67)	(56, 67)	(16, 42)	(16, 28)	(12, 25)
n	63	1376	396	63	1376	396	63	1376	396
Uganda 1	96	96	.	34	36	.	9	9	.
Conf. interval	(95, 98)	(96, 97)	.	(30, 39)	(34, 39)	.	(6, 11)	(8, 11)	.
n	526	2218	.	526	2218	.	526	2218	.
Uganda 2	97	96	97	20	30	28	8	11	13
Conf. interval	(94, 99)	(95, 97)	(94, 100)	(14, 26)	(27, 33)	(21, 36)	(4, 11)	(9, 13)	(7, 19)
n	173	749	123	173	749	123	173	749	123
All LMICs	89	89	93	33	39	36	15	13	13
Conf. interval	(81, 97)	(81, 98)	(89, 98)	(25, 41)	(29, 48)	(23, 48)	(10, 20)	(8, 18)	(7, 19)
n	1838	8749	1084	1838	8749	1084	1838	8749	1084
Russia	67	76	81	74	68	68	46	40	38
Conf. interval	(59, 74)	(73, 78)	(76, 87)	(68, 81)	(66, 71)	(62, 74)	(38, 54)	(38, 43)	(32, 44)
n	552	5108	227	552	5108	227	552	5108	227
USA	92	91	97	89	91	94	90	89	89
Conf. interval	(88, 96)	(89, 94)	(95, 99)	(83, 95)	(88, 93)	(91, 97)	(85, 95)	(86, 92)	(85, 93)
n	153	687	473	153	687	473	153	687	473

Table 6 shows percentage of respondents mentioning reasons why they would take the Covid-19 vaccine by age groups. The number of observations and percentage corresponds only to people who would take the vaccine. Respondents in all countries could give more than one reason. A 95% confidence interval is shown between parentheses

Table 7: Reasons not to take the vaccine

Study	N	Concerned about side effects	Concerned about getting coronavirus from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines are effective	Doesn't think Coronavirus outbreak is as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Mentions a conspiracy theory	Other reasons
Burkina Faso	325	40.9 (35.5, 46.3)	8.0 (5.0, 11.0)	7.4 (4.5, 10.2)	19.5 (15.1, 23.8)	13.5 (9.8, 17.2)	3.5 (1.5, 5.6)	1.5 (0.2, 2.8)	0.9 (-0.1, 1.9)	17.9 (13.7, 22.1)	8.7 (5.6, 11.8)
Colombia	202	31.0 (24.4, 37.6)	18.1 (12.7, 23.4)	8.0 (3.9, 12.0)	10.2 (5.9, 14.5)	2.3 (0.3, 4.3)	0.6 (-0.6, 1.8)	0.4 (-0.4, 1.3)	0.5 (-0.5, 1.5)	10.0 (5.8, 14.2)	31.6 (25.1, 38.2)
Mozambique	74	. (0.3, 18.2)	. (-0.4, 16.3)	2.7 (-0.7, 6.1)	29.7 (18.6, 40.8)	. (3.2, 27.2)	. (-1.9, 10.6)	. (-1.9, 5.5)	. (-0.4, 1.3)	. (5.8, 14.2)	21.6 (12.2, 31.0)
Nepal	48	9.3 (0.3, 18.2)	7.9 (-0.4, 16.3)	20.4 (6.7, 34.1)	15.2 (3.2, 27.2)	15.7 (4.0, 27.3)	4.4 (-1.9, 10.6)	1.8 (-1.9, 5.5)	. (-0.4, 1.3)	2.8 (5.8, 14.2)	12.1 (5.6, 11.8)
Nigeria	410	21.5 (17.5, 25.5)	26.1 (21.8, 30.4)	15.9 (12.3, 19.4)	9.3 (6.4, 12.1)	. (6.4, 12.1)	. (6.4, 12.1)	0.2 (-0.2, 0.7)	. (6.4, 12.1)	4.9 (2.8, 7.0)	26.8 (22.5, 31.1)
Pakistan 1	441	23.0 (15.1, 30.8)	21.9 (14.3, 29.4)	29.4 (20.9, 37.9)	26.0 (18.0, 34.0)	22.1 (12.8, 31.3)	11.5 (5.5, 17.4)	. (5.5, 17.4)	. (5.5, 17.4)	13.2 (7.1, 19.4)	19.6 (10.4, 28.8)
Rwanda	70	38.6 (26.9, 50.3)	10.1 (2.8, 17.3)	18.7 (9.3, 28.1)	21.5 (11.6, 31.4)	5.8 (0.1, 11.4)	7.0 (0.9, 13.2)	5.6 (0.1, 11.1)	. (0.1, 11.1)	21.3 (11.5, 31.1)	25.8 (15.3, 36.3)
Sierra Leone 1	234	53.5 (47.1, 59.9)	37.9 (31.6, 44.2)	14.6 (10.1, 19.2)	7.5 (4.2, 10.9)	4.2 (1.6, 6.8)	3.0 (0.8, 5.2)	0.9 (-0.4, 2.2)	4.0 (1.4, 6.5)	20.3 (15.1, 25.5)	5.7 (2.8, 8.7)
Sierra Leone 2	254	57.9 (50.1, 65.7)	. (0.3, 18.2)	. (-0.4, 16.3)	17.3 (11.9, 22.7)	. (3.2, 27.2)	5.1 (-1.9, 10.6)	. (-1.9, 5.5)	0.0 (-0.4, 1.3)	3.5 (5.8, 14.2)	24.8 (12.2, 31.0)
Uganda 1	289	85.1 (80.7, 89.6)	. (0.3, 18.2)	3.8 (-0.4, 16.3)	24.2 (19.2, 29.2)	1.7 (0.2, 3.2)	1.7 (-1.9, 10.6)	. (-1.9, 5.5)	1.0 (-0.4, 1.3)	. (5.8, 14.2)	8.0 (5.6, 11.8)
Uganda 2	319	47.3 (42.2, 52.5)	10.7 (7.1, 14.2)	5.0 (2.7, 7.3)	31.0 (25.9, 36.2)	4.1 (1.9, 6.2)	1.6 (0.2, 2.9)	0.3 (-0.3, 0.9)	. (7.0, 13.7)	10.3 (3.4, 8.5)	6.0 (3.4, 8.5)
All LMICs	.	40.8 (25.3, 56.3)	17.6 (8.7, 26.5)	12.6 (6.4, 18.8)	19.2 (13.8, 24.7)	8.7 (2.4, 14.9)	4.3 (1.7, 6.8)	1.5 (-0.2, 3.3)	1.3 (-0.6, 3.2)	11.6 (6.1, 17.0)	17.3 (11.0, 23.7)
Russia	16238	36.8 (35.2, 38.4)	13.9 (12.8, 15.1)	5.4 (4.6, 6.1)	29.6 (28.1, 31.1)	6.4 (5.6, 7.3)	3.7 (3.1, 4.3)	10.2 (9.2, 11.2)	1.0 (0.7, 1.4)	21.4 (20.1, 22.8)	5.1 (4.4, 5.8)
USA	462	79.3 (74.6, 84.0)	. (0.3, 18.2)	39.3 (33.5, 45.0)	46.8 (41.0, 52.6)	. (3.2, 27.2)	. (-1.9, 10.6)	. (-1.9, 5.5)	. (-0.4, 1.3)	6.0 (3.4, 8.7)	49.1 (43.3, 54.9)

Table 7 shows percentage of respondents mentioning reasons why they would not take the Covid-19 vaccine. The number of observations and percentage corresponds only to people who would NOT take the vaccine. Respondents in all countries could give more than one reason. A 95% confidence interval is shown between parentheses

Table 8: COVID-19 Vaccination Decision-making: most trusted source

Study	N	Take vaccine?	Health workers	Government or Ministry of Health	Family or friends	Famous person, religious leader or traditional healers	Newspapers, radio or online groups	Other	Don't know or Refuse
Burkina Faso	651	Yes	57.1 (53.3, 60.9)	15.1 (12.4, 17.9)	19.6 (16.5, 22.7)	0.9 (0.2, 1.6)	2.0 (0.9, 3.1)	4.8 (3.2, 6.4)	0.4 (-0.1, 0.9)
Burkina Faso	325	No	40.7 (35.3, 46.1)	8.5 (5.5, 11.6)	16.2 (12.1, 20.2)	3.7 (1.6, 5.7)	1.6 (0.2, 3.0)	25.1 (20.3, 29.8)	4.2 (2.0, 6.4)
Burkina Faso	976	All	51.6 (48.5, 54.8)	12.9 (10.8, 15.0)	18.4 (16.0, 20.9)	1.8 (1.0, 2.7)	1.9 (1.0, 2.7)	11.6 (9.6, 13.6)	1.7 (0.9, 2.5)
Colombia	756	Yes	41.4 (37.8, 45.0)	12.7 (10.3, 15.2)	36.9 (33.4, 40.4)	0.9 (0.2, 1.5)	1.7 (0.8, 2.7)	.	6.3 (4.6, 8.1)
Colombia	202	No	31.5 (24.9, 38.1)	7.6 (3.8, 11.3)	35.5 (28.8, 42.1)	5.3 (2.2, 8.4)	1.4 (-0.2, 3.0)	.	18.8 (13.2, 24.3)
Colombia	958	All	39.3 (36.2, 42.5)	11.6 (9.6, 13.7)	36.6 (33.5, 39.7)	1.8 (1.0, 2.6)	1.7 (0.9, 2.5)	.	8.9 (7.1, 10.7)
Nepal	1341	Yes	44.7 (40.9, 48.6)	0.7 (0.3, 1.1)	36.2 (33.5, 39.0)	16.1 (13.1, 19.1)	0.4 (0.0, 0.9)	0.5 (0.1, 0.8)	1.3 (0.7, 2.0)
Nepal	48	No	30.2 (14.6, 45.9)	2.1 (-2.1, 6.2)	18.7 (5.6, 31.7)	16.8 (4.0, 29.6)	0.0 (0.0, 0.0)	1.0 (-1.1, 3.2)	31.2 (13.6, 48.9)
Nepal	1389	All	44.2 (40.5, 47.9)	0.8 (0.3, 1.2)	35.6 (32.9, 38.3)	16.1 (13.3, 18.9)	0.4 (0.0, 0.8)	0.5 (0.1, 0.8)	2.4 (1.5, 3.3)
Nigeria	1424	Yes	63.8 (61.3, 66.3)	21.6 (19.4, 23.7)	6.3 (5.0, 7.5)	5.1 (4.0, 6.3)	.	2.6 (1.8, 3.4)	0.6 (0.2, 1.0)
Nigeria	410	No	37.6 (32.9, 42.3)	5.6 (3.4, 7.8)	13.9 (10.5, 17.3)	17.8 (14.1, 21.5)	.	8.5 (5.8, 11.3)	16.6 (13.0, 20.2)
Nigeria	1834	All	58.0 (55.7, 60.2)	18.0 (16.2, 19.8)	8.0 (6.7, 9.2)	8.0 (6.7, 9.2)	.	3.9 (3.0, 4.8)	4.2 (3.3, 5.1)
Rwanda	1152	Yes	23.8 (21.3, 26.2)	27.4 (24.9, 30.0)	15.1 (13.0, 17.2)	1.0 (0.4, 1.5)	0.7 (0.2, 1.2)	32.0 (29.3, 34.7)	0.1 (-0.1, 0.2)
Rwanda	70	No	10.1 (2.8, 17.4)	15.6 (6.9, 24.3)	12.8 (4.8, 20.8)	2.9 (-1.1, 6.9)	0.0 (0.0, 0.0)	53.2 (41.2, 65.1)	5.5 (0.1, 11.0)
Rwanda	1222	All	23.0 (20.6, 25.3)	26.7 (24.3, 29.2)	15.0 (13.0, 17.0)	1.1 (0.5, 1.7)	0.6 (0.2, 1.1)	33.2 (30.5, 35.8)	0.4 (0.0, 0.8)

Table 8: COVID-19 Vaccination Decision-making: most trusted source (*continued*)

Study	N	Take vaccine?	Health workers	Government or Ministry of Health	Family or friends	Famous person, religious leader or traditional healers	Newspapers, radio or online groups	Other	Don't know or Refuse
Sierra Leone 1	836	Yes	47.6 (44.2, 51.0)	36.9 (33.6, 40.2)	7.3 (5.5, 9.1)	3.8 (2.5, 5.1)	0.5 (0.0, 1.0)	3.1 (1.9, 4.2)	0.8 (0.2, 1.4)
Sierra Leone 1	234	No	31.1 (25.1, 37.1)	17.1 (12.2, 21.9)	12.1 (7.9, 16.3)	7.7 (4.3, 11.2)	0.5 (-0.4, 1.3)	29.4 (23.5, 35.3)	2.2 (0.3, 4.1)
Sierra Leone 1	1070	All	44.0 (41.0, 46.9)	32.5 (29.7, 35.4)	8.4 (6.7, 10.0)	4.7 (3.4, 6.0)	0.5 (0.1, 0.9)	8.9 (7.1, 10.6)	1.1 (0.5, 1.8)
Sierra Leone 2	1855	Yes	94.1 (92.5, 95.7)	. (. , .)	3.0 (2.0, 4.0)	0.9 (0.3, 1.5)	0.1 (-0.1, 0.2)	1.9 (1.2, 2.7)	0.0 (0.0, 0.0)
Sierra Leone 2	254	No	54.7 (46.5, 62.9)	. (. , .)	3.9 (1.4, 6.5)	7.5 (2.9, 12.0)	0.0 (0.0, 0.0)	33.9 (26.3, 41.4)	0.0 (0.0, 0.0)
Sierra Leone 2	2109	All	89.3 (87.2, 91.5)	. (. , .)	3.1 (2.2, 4.1)	1.7 (0.8, 2.6)	0.0 (0.0, 0.1)	5.8 (4.4, 7.2)	0.0 (0.0, 0.0)
Uganda 2	1045	Yes	38.3 (35.5, 41.1)	36.5 (33.5, 39.4)	9.8 (7.9, 11.6)	7.0 (5.4, 8.6)	5.0 (3.6, 6.3)	3.5 (2.5, 4.6)	0.0 (0.0, 0.0)
Uganda 2	319	No	24.5 (19.9, 29.0)	19.1 (14.5, 23.7)	8.5 (5.4, 11.5)	7.8 (4.8, 10.9)	7.5 (4.5, 10.5)	32.0 (26.7, 37.3)	0.6 (-0.2, 1.5)
Uganda 2	1364	All	35.0 (32.7, 37.4)	32.4 (29.9, 35.0)	9.5 (7.9, 11.1)	7.2 (5.8, 8.6)	5.6 (4.3, 6.8)	10.2 (8.6, 11.8)	0.1 (-0.1, 0.3)
All LMICs	.	Yes	51.3 (33.7, 68.9)	21.6 (9.4, 33.8)	16.8 (5.7, 27.9)	4.5 (0.1, 8.8)	1.5 (-0.1, 3.1)	6.9 (-3.4, 17.2)	1.2 (-0.6, 3.0)
All LMICs	.	No	32.5 (21.8, 43.3)	10.8 (4.8, 16.8)	15.2 (7.4, 23.0)	8.7 (4.0, 13.4)	1.6 (-0.9, 4.1)	26.1 (10.2, 42.1)	9.9 (0.6, 19.2)
All LMICs	.	All	48.1 (31.6, 64.5)	19.3 (8.3, 30.3)	16.8 (6.1, 27.5)	5.3 (1.0, 9.6)	1.5 (-0.2, 3.3)	10.6 (0.7, 20.5)	2.4 (-0.1, 4.9)
Russia	5887	Yes	47.1 (44.6, 49.7)	24.4 (22.2, 26.7)	16.5 (14.6, 18.5)	2.0 (1.2, 2.8)	4.1 (3.1, 5.1)	5.8 (4.5, 7.0)	. (. , .)
Russia	16238	No	31.1 (29.6, 32.7)	6.9 (6.1, 7.8)	33.1 (31.5, 34.7)	2.2 (1.7, 2.8)	5.3 (4.5, 6.0)	21.3 (20.0, 22.7)	. (. , .)
Russia	22125	All	36.0 (34.7, 37.3)	12.3 (11.3, 13.2)	28.1 (26.8, 29.3)	2.2 (1.7, 2.6)	4.9 (4.3, 5.5)	16.6 (15.6, 17.6)	. (. , .)

Table 8: COVID-19 Vaccination Decision-making: most trusted source (*continued*)

Study	N	Take vaccine?	Health workers	Government or Ministry of Health	Family or friends	Famous person, religious leader or traditional healers	Newspapers, radio or online groups	Other	Don't know or Refuse
USA	1313	Yes	38.1 (34.8, 41.5)	33.0 (29.8, 36.1)	8.7 (6.7, 10.7)	1.7 (0.7, 2.6)	.	18.6 (16.1, 21.1)	0.0 (0.0, 0.0)
USA	462	No	25.3 (20.4, 30.3)	21.3 (16.6, 26.0)	18.7 (13.9, 23.4)	4.2 (1.6, 6.9)	.	30.3 (25.0, 35.6)	0.2 (-0.2, 0.7)
USA	1775	All	34.5 (31.7, 37.3)	29.7 (27.0, 32.3)	11.5 (9.5, 13.4)	2.4 (1.4, 3.4)	.	21.9 (19.5, 24.2)	0.1 (-0.1, 0.2)

Table 8 shows percentage of respondents that mention actors who they would trust the most to help them decide whether to get a COVID-19 vaccine. For all countries the questions was asked regardless if respondent would take a vaccine, would not take it, does not know or does not respond. For India respondents were able to mention more than one actor, for the rest of countries only one actor was allowed. While rows should sum to 100%, rounding makes number slightly above or below. A 95% confidence interval is shown between parentheses.

Figure 4: Trusted actors and institutions, broken down by gender

Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine?




Figure 4 shows histograms of actors and institutions that respondents say they would trust most to help them decide whether or not to take the COVID-19 vaccine. Respondents were only permitted to select one most trusted actor or institution. Responses are broken down by acceptance of the COVID-19 vaccine. The color of the bars reflect the answer given to the question “If a COVID-19 vaccine becomes available in [country], would you take it?” with “No” and “Don’t know” pooled together and “All” combined average of “Yes” and “No / Don’t know”

Figure 5: Trusted actors and institutions, broken down by vaccine acceptance

Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine?



Figure 5 shows histograms of actors and institutions that respondents say they would trust most to help them decide whether or not to take the COVID-19 vaccine. Respondents were only permitted to select one most trusted actor or institution. Responses are broken down by acceptance of the COVID-19 vaccine. The color of the bars reflect the answer given to the question “If a COVID-19 vaccine becomes available in [country], would you take it?” with “No” and “Don’t know” pooled together and “All” combined average of “Yes” and “No / Don’t know”

Table 9: Differences in means

Estimate	Std.error	P.value	Degrees of freedom	Baseline category	Variable
0.04	0.01	0.00	10	Male	Gender (Female)
-0.02	0.02	0.43	10	<25	Age (25-54)
-0.02	0.02	0.36	10	<25	Age (55+)
0.02	0.03	0.38	10	Up to secondary	Education (Secondary +)

Table 9 shows the results of subgroup mean differences. Subgroup differences were generated considering only LMICs. p-values come from a two-sided t-test from a linear regression.

Table 10: Observations and missingness patterns

Country	N obs	Take vaccine	Gender	Education	Age
Burkina Faso	977	99.90	100.00	100.00	12.28
Colombia	1,012	94.66	100.00	99.90	68.18
India	1,680	100.00	100.00	20.24	100.00
Mozambique	862	97.68	100.00	96.06	99.77
Nepal	1,389	100.00	95.32	0.00	95.32
Nigeria	1,868	98.18	100.00	0.00	100.00
Pakistan 1	1,633	98.96	99.76	99.27	100.00
Pakistan 2	1,492	99.87	0.00	100.00	0.00
Russia	22,125	100.00	100.00	100.00	100.00
Rwanda	1,355	90.18	100.00	100.00	100.00
Sierra Leone 1	1,070	100.00	100.00	97.01	100.00
Sierra Leone 2	2,110	99.95	100.00	100.00	98.91
Uganda 1	3,362	94.41	100.00	81.47	95.12
Uganda 2	1,366	99.85	100.00	100.00	100.00
USA	1,959	90.61	100.00	100.00	100.00

Table 10 show the proportion of observations that are not missing values for each variable included in Figure 1.

Table 11: Differences between groups within studies

Country	Variable	Baseline category	Group	Estimate	Std. Error	p.value	Degrees of freedom
Burkina Faso	Age	<25	25-54	-0.13	0.10	0.21	117
Colombia	Age	<25	25-54	-0.01	0.05	0.79	687
India	Age	<25	25-54	0.08	0.03	0.00	1,677
Mozambique	Age	<25	25-54	-0.12	0.01	0.00	857
Nepal	Age	<25	25-54	-0.01	0.01	0.34	1,321
Nigeria	Age	<25	25-54	0.09	0.03	0.01	1,865
Pakistan 1	Age	<25	25-54	-0.11	0.07	0.15	1,630
Russia	Age	<25	25-54	-0.06	0.02	0.01	22,122
Rwanda	Age	<25	25-54	-0.04	0.02	0.03	1,352
Sierra Leone 1	Age	<25	25-54	0.00	0.03	0.94	1,067
Sierra Leone 2	Age	<25	25-54	0.05	0.04	0.29	2,084
Uganda 1	Age	<25	25-54	0.00	0.02	0.83	3,196
Uganda 2	Age	<25	25-54	0.00	0.03	0.89	1,363
USA	Age	<25	25-54	0.14	0.04	0.00	1,956
Burkina Faso	Age	<25	55+	-0.15	0.26	0.56	117
Colombia	Age	<25	55+	-0.02	0.06	0.79	687
India	Age	<25	55+	0.05	0.04	0.17	1,677
Mozambique	Age	<25	55+	-0.08	0.02	0.00	857
Nepal	Age	<25	55+	-0.04	0.02	0.07	1,321
Nigeria	Age	<25	55+	0.06	0.05	0.28	1,865
Pakistan 1	Age	<25	55+	-0.06	0.11	0.61	1,630
Russia	Age	<25	55+	0.07	0.03	0.03	22,122
Rwanda	Age	<25	55+	-0.15	0.07	0.04	1,352
Sierra Leone 1	Age	<25	55+	-0.04	0.07	0.56	1,067
Sierra Leone 2	Age	<25	55+	0.07	0.05	0.12	2,084
Uganda 2	Age	<25	55+	-0.03	0.04	0.51	1,363
USA	Age	<25	55+	0.18	0.04	0.00	1,956
Burkina Faso	Education	Secondary +	Up to secondary	0.09	0.03	0.00	975
Colombia	Education	Secondary +	Up to secondary	-0.05	0.03	0.10	1,009
India	Education	Secondary +	Up to secondary	-0.02	0.04	0.60	338
Mozambique	Education	Secondary +	Up to secondary	0.04	0.03	0.24	826
Pakistan 1	Education	Secondary +	Up to secondary	-0.10	0.03	0.00	1,619
Pakistan 2	Education	Secondary +	Up to secondary	-0.07	0.03	0.00	1,490
Russia	Education	Secondary +	Up to secondary	-0.01	0.01	0.31	22,123
Rwanda	Education	Secondary +	Up to secondary	0.16	0.03	0.00	1,353
Sierra Leone 1	Education	Secondary +	Up to secondary	0.06	0.03	0.03	1,036
Sierra Leone 2	Education	Secondary +	Up to secondary	-0.01	0.02	0.64	2,108
Uganda 1	Education	Secondary +	Up to secondary	0.05	0.03	0.07	2,737
Uganda 2	Education	Secondary +	Up to secondary	0.11	0.03	0.00	1,364
USA	Education	Secondary +	Up to secondary	-0.21	0.03	0.00	1,957
Burkina Faso	Gender	Female	Male	0.06	0.03	0.06	975
Colombia	Gender	Female	Male	0.04	0.03	0.18	1,010
India	Gender	Female	Male	0.02	0.02	0.22	1,678
Mozambique	Gender	Female	Male	0.05	0.02	0.02	860
Nepal	Gender	Female	Male	0.00	0.01	0.98	1,322
Nigeria	Gender	Female	Male	0.02	0.02	0.30	1,866
Pakistan 1	Gender	Female	Male	0.08	0.03	0.01	1,627
Russia	Gender	Female	Male	0.16	0.01	0.00	22,123
Rwanda	Gender	Female	Male	0.09	0.02	0.00	1,353
Sierra Leone 1	Gender	Female	Male	0.06	0.03	0.03	1,068
Sierra Leone 2	Gender	Female	Male	-0.01	0.02	0.59	2,108
Uganda 2	Gender	Female	Male	0.03	0.02	0.18	1,364
USA	Gender	Female	Male	0.17	0.03	0.00	1,957

Table 11 shows differences of means between groups within single studies. Estimates are calculated through OLS and represent the difference in the average acceptance rate between the subgroup in column Group and that in column Baseline category.

Appendix B: Question wording and answer options per study

Table 12: Question wording and answer options: vaccine acceptance

Study	Question Fig. 1	Recoding Fig. 1
Burkina Faso	If a COVID-19 vaccine became available in Burkina Faso, would you take it?	Yes; No; Don't know; Refuse
Colombia	If a COVID-19 vaccine became available in Colombia, would you take it?	Yes; No
India	If a vaccine for coronavirus gets introduced, would you like to get it?	Yes, only for free; Yes, even if I have to pay; No
Mozambique	When a COVID-19 vaccine becomes available in the future, would you take it?	Yes; No; Refuse
Nepal	Should a vaccine against COVID become available in Nepal, would you take it?	Yes; No
Nigeria	If a COVID-19 vaccine became available in Niger, would you take it?	Yes/Agree; No/Disagree
Pakistan 1	If a vaccine against the coronavirus becomes available, do you plan to get vaccinated?	Yes; No; Don't know; Refuse
Pakistan 2	If a vaccine against the coronavirus becomes available, do you plan to get vaccinated?	Absolutely yes; Yes; Neutral; No; Absolutely no
Russia	If a COVID-19 vaccine became available in Russia, would you take it?	Yes, if a Russian vaccine will be available; Yes, if an imported vaccine will be available; No; Not sure
Rwanda	If a COVID-19 vaccine became available in Rwanda, would you take it?	Yes; No
Sierra Leone 1	If a COVID-19 vaccine became available in Sierra Leone, would you take it?	Yes; No
Sierra Leone 2	Should a vaccine against COVID become available in Sierra Leone, would you take it?	Yes; No
Uganda 1	When a COVID-19 vaccine becomes available in Uganda, would you take it?	Yes; No
Uganda 2	If a COVID-19 vaccine becomes available in Uganda, would you take it?	Yes; No; Don't know; Refuse
USA	If a COVID-19 vaccine becomes available in the United States, would you take it?	Definitely yes; Probably yes; Probably not; Definitely not, Refuse

Table 12 presents question wording and answer options from answers used in Figure 1 to get estimated vaccine acceptance. Answer options are separated by a semicolon. In India options 'Yes, only for free' and 'Yes, even if I have to pay' are both recoded as 'Yes'. In Pakistan 2, 'Absolutely yes' is recoded as 'Yes', 'Neutral' is recoded as 'Don't know' and 'Absolutely no' is recoded as 'No'. In Russia, 'Yes, if a Russian vaccine will be available' and 'Yes, if an imported vaccine will be available' are both recoded as 'Yes'. In USA 'Definitely yes' and 'Probably yes' are recoded as 'Yes', and 'Probably not' and 'Definitely not' are recoded as 'No'.

Table 13: Question wording and answer options: reasons to take vaccine

Study	Question Tab. 2	Protection: self	Protection: family	Protection: community
Burkina Faso	Why would you take it?	Protection: self (general); Protection: self, chronic condition	Protection: family	Protection: community
Colombia	Why would you take it?	Protection: self (general); Protection: self, chronic condition	Protection: family	Protection: community
Mozambique	Why would you take it?	I want to protect myself from having COVID-19 in the future	I want to protect my family/members of my household against having COVID-19 in the future	I want to protect my community against having COVID-19 in the future
Nepal	Why would you take it?	Protection: self (general); Protection: self, chronic condition/ vulnerable to covid	Protection: family	Protection: community
Nigeria	Why would you take it?	I want to protect myself from having COVID-19 in the future	I want to protect my family/members of my household against having COVID-19 in the future	I want to protect my community against having COVID-19 in the future
Russia	Why would you take it?	Protection: self	Protection: family	Protection: community
Rwanda	Why would you take it?	Protection: self (general); Protection: self, chronic condition	Protection: family	Protection: community
Sierra Leone 1	Why would you take it?	Protection: self (general); Protection: self, chronic condition	Protection: family	Protection: community
Sierra Leone 2	Why would you take it?	I will take a vaccine to protect myself from having COVID-19 in the future	I will take a vaccine to protect my family/members of my household against having COVID-19 in the future	I will take a vaccine to protect my community against having COVID-19 in the future
Uganda 1	Why would you take it?	Protect myself from having COVID-19	Protect my family/members of my household against COVID-19	Protect my community against COVID-19
Uganda 2	Why would you take it?	Protection: self (general); Protection: self, chronic condition/ vulnerable to Covid	Protection: family	Protection: community
USA	Why would you take it?	To protect myself from COVID-19 infection	To protect my family from COVID-19 infection	To protect my community from COVID-19 infection

Table 13 presents question wording and answer options used in Table 2 to get an estimated percentage of reasons to take the COVID-19 vaccine. Columns 'Protection: self', 'Protection: family' and 'Protection: community' show the answer options that were recoded in each category. Answer options are separated by a semicolon.

Table 14: Question wording and answer options: reasons not to take the vaccine

Study	Question Fig. 2	Concerned about side effects	Concerned about getting COVID-19 from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines are effective	Doesn't think COVID-19 outbreak is as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Mentions a conspiracy theory	Other reasons
Burkina Faso	Why would you not take it?	.	Concerned about getting coronavirus from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines work very well	Coronavirus outbreak is not as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Conspiracy theory	Other reason
Colombia	Why would you not take it?	.	Concerned about getting coronavirus from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines work very well	Coronavirus outbreak is not as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Conspiracy theory	Other reason; Already immune; Doesn't have symptoms
Mozambique	Why would you not take it?	.	.	I am not concerned about the risk associated with me/my relatives getting COVID-19	I don't think vaccines are effective	The coronavirus outbreak is not as serious as people say it is	I don't like needles	.	I won't have time to go get vaccinated	.	Other
Nepal	Why would you not take it?	I would be concerned about the side effects from the vaccine	I would be concerned about getting infected with coronavirus from the vaccine	I'm not concerned about getting seriously ill from the virus	I don't think vaccines work very well	The coronavirus outbreak is not as serious as people say it is	I don't like needles	I'm allergic to vaccines	I won't have time to go get vaccinated	I think there is a conspiracy theory with vaccinations	Other
Nigeria	Why would you not take it?	I would be concerned about the side effects from the vaccine	I would be concerned about getting infected with coronavirus from the vaccine	I'm not concerned about getting seriously ill from the virus	I don't think vaccines work very well	The coronavirus outbreak is not as serious as people say it is	I don't like needles	I'm allergic to vaccines	I won't have time to go get vaccinated	The virus is a hoax / does not exist; The vaccine has microchips/tracking devices	Other; Religious / community leaders advising me not to take it
Pakistan 1	Why would you not take it?	I am concerned about side effects from the vaccine	I would be concerned about getting infected with coronavirus from the vaccine	I don't consider myself or my family members at risk of getting seriously ill	I don't think the vaccine would work well	The coronavirus infection is just like the flu and doesn't warrant a vaccine	I don't like needles	.	.	Western conspiracies to stunt the growth of Muslims	Muslims are prohibited from taking a vaccine before a disease is contracted
Russia	Why would you not take it?	Afraid of side effects	Afraid of getting infected with coronavirus from the vaccine	Not concerned with getting seriously ill from the virus	Don't think vaccines are effective	Coronavirus outbreak is not as serious as people say it is	Afraid of needles	Can get allergic reaction	Don't have time to get vaccinated	Hoax: Virus don't exist; Hoax: Virus was designed so vaccines won't work; Profit motivation: pharmaceutical companies; Control: contain things that control our minds; Global politics: China can take advantage	Other; I already had coronavirus and don't need a vaccine
Rwanda	Why would you not take it?	.	Concerned about getting coronavirus from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines work very well	Coronavirus outbreak is not as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Conspiracy theory	Other reason; Already immune; Doesn't have symptoms
Sierra Leone 1	Why would you not take it?	.	Concerned about getting coronavirus from the vaccine	Not concerned about getting seriously ill	Doesn't think vaccines work very well	Coronavirus outbreak is not as serious as people say	Doesn't like needles	Allergic to vaccines	Won't have time to get vaccinated	Conspiracy theory	Other reason
Sierra Leone 2	Why would you not take it?	I will not take a vaccine because I am concerned about side effects	I will not take a vaccine because I am not concerned about the risk associated with me/my relatives getting COVID-19	I will not take a vaccine because I am not concerned about the risk associated with me/my relatives getting COVID-19	I will not take a vaccine because they are not effective	.	I will not take a vaccine because I don't like needles	.	I will not take a vaccine because I don't have time	I will not take a vaccine because I don't think COVID exists	I will not take a vaccine because of other reasons; I will not take a vaccine because my community objects it; I will not take a vaccine because I don't have symptoms; I will not take a vaccine because I am immune; I will not take a vaccine because it is provided by foreign aid; I will not take a vaccine because I don't know what a vaccine is
Uganda 1	Why would you not take it?	Concerned about the side effects from the vaccine/vaccines	I am not worried that my relatives will get COVID-19	I am not worried that my relatives will get COVID-19	I don't think vaccines are effective	Coronavirus is not as serious as people say it is	I don't like needles	.	I won't have time to go get vaccinated	.	Other; It will cost too much
Uganda 2	Why would you not take it?	I would be concerned about the side effects from the vaccine	I would be concerned about getting infected with coronavirus from the vaccine	I'm not concerned about getting seriously ill from the virus	I don't think vaccines work very well	The coronavirus outbreak is not as serious as people say it is	I don't like needles	I'm allergic to vaccines	I won't have time to go get vaccinated	I think there is a conspiracy theory with vaccinations	Other
USA	Why would you not take it?	I am concerned about possible side effects	.	I am not concerned about getting the virus	I don't think vaccines are effective	.	.	.	.	Mentions a conspiracy theory (recoded from responses in "Other" category)	Cost or difficulty of getting the vaccine

Table 14 presents question wording and answer options used in Figure 2 to get an estimated percentage of reasons not to take the COVID-19 vaccine. Columns 3-10 show the answer options that were recoded in each category. Answer options are separated by a semicolon.

Table 15: Question wording and answer options: trusted actors and institutions

Study	Question Fig. 3	Health workers	Government or Ministry of Health	Family or friends	Famous person, religious leader or traditional healers	Newspapers, radio or online groups	Other
Burkina Faso	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice from Ministry of Health	Family members; Friends you see and talk to; Friends you've made online	Famous person; Religious leaders; Traditional Healers	Traditional media (newspaper, radio); Online medical discussion groups	Other/ Someone else
Colombia	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice of the Instituto Nacional de Salud	Family members; Friends you see and talk to; Friends you've made online	Famous person; Religious leaders; Traditional Healers	Traditional media (newspaper, radio); Online medical discussion groups	Other/ Someone else
Nepal	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice of the national health service	Family members; Friends you see and talk to	Famous person; Religious leaders; Traditional healers	Traditional media (newspaper, radio); Online medical discussion groups	None of these/ Someone else; Advice of the WHO
Nigeria	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Medical professionals like doctors	NCDC; Government officials	Family members and friends	Religious leaders	.	Some other sourcer; Other community leaders
Russia	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Health workers	Government; Health Ministry	Family; Friends	Famous people; Religious leaders	Traditional media; Online medical discussion groups	Other
Rwanda	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice of the Ministry of Health	Family members; Friends you see and talk to; Friends you've made online	Famous person; Religious leaders; Traditional healers	Traditional media (newspaper, radio); Online medical discussion groups	None of these/ Someone else; Myself
Sierra Leone 1	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice of the Ministry of Health and Sanitation	Family members; Friends you see and talk to; Friends you've made online	Famous person; Religious leaders; Traditional healers	Traditional media (newspaper, radio); Online medical discussion groups	None of these/ Someone else; I do trust NOBODY
Sierra Leone 2	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	A doctor, nurse or other staff at a community health clinic; A country medical staff	.	Family; Friends you see and talk to; Friends you've made online	A famous person; A religious leader; A traditional healer	Online medical discussion groups	None of these/ Someone else
Uganda 2	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Doctors or other staff at a community health clinic	Advice of the national health service	Family; Friends you see and talk to; Friends you've made online	Famous person; Religious leaders; Traditional healers	Traditional media (newspaper, radio); Online medical discussion groups	None of these; Someone else
USA	Which of the following people would you trust MOST to help you decide whether you would get a COVID-19 vaccine, if one becomes available?	Your doctor or healthcare provider	Donald Trump; Anthony Fauci; Your state's governor; Local public health authority	Friends or family	Your pastor, priest, or other religious leader	.	Other; Joe Biden

Table 15 presents question wording and answer options used in Figure 3 to get the percentage of respondents mentioning each actor or institution that they would trust to decide whether to get the COVID-19 vaccine. Columns 3-8 show the answer options that were recoded in each category. Answer options are separated by a semicolon.

Appendix C: Sample descriptions

The case history data for all countries in our sample is extracted from the Johns Hopkins University Center for Systems Science and Engineering (JHU CSSE) database.¹

Burkina Faso, Research for Effective COVID-19 Responses (RECOVR) National RDD Sample, Innovations for Poverty Action (IPA)

COVID-19 Experience

- First confirmed case: March 9, 2020
- Number of confirmed cases 2,335 as of October 15, 2020
- Number of deaths: 65 as of October 15, 2020

Target Population: A random sample of all adults with mobile phone numbers in the country, based on national communications authority number allocation plans.

Original Study Design: N/A

COVID-19 Survey Design: Numbers were called via random digit dialing (RDD), stratified by mobile network operator market share for a two-round panel survey.

Sampling Frame: All mobile phone numbers in Burkina Faso.

Survey Dates: October 15 to December 4, 2020 (Round 1 June 6-15, 2020)

Sample size, tracking and attrition: Sample includes 977 respondents from the second round of a panel. In the first round conducted between June 6 to 15, 2020, 1,356 individual surveys were contacted through Random Digit Dialing (RDD) from the sampling frame of all mobile phone numbers in Burkina Faso. 2,313 working numbers yielded 1,383 eligible respondents for a completion rate of 98% of eligible respondents.

Sampling Weights: Post-stratification weights are computed to adjust for differential attrition between the first and second rounds of the RDD panel, weighting on gender, region, and educational attainment.

IRB Approval: This research was approved via IPA IRB Protocol 15608, and the Burkina Faso Institutional Ethics Committee for Health Sciences Research, approval A13-2020.

Colombia, Research for Effective COVID-19 Responses (RECOVR) National RDD Sample, Innovations for Poverty Action (IPA)

COVID-19 Experience

¹Dong, E., Du, H., & Gardner, L. (2020). An interactive web-based dashboard to track COVID-19 in real time. The Lancet infectious diseases, 20(5), 533-534.

- First confirmed case: March 6, 2020
- Number of confirmed cases: 456,689 as of August 15, 2020
- Number of deaths: 14,810 as of August 15, 2020

Target Population: A random sample of all numerically possible mobile phone numbers in the country, based on national communications authority number allocation plans.

Original Study Design: N/A

COVID-19 Survey Design:

Sampling Frame: Numbers were called via random digit dialing (RDD), stratified by mobile network operator market share.

Survey Dates: August 15-25, 2020 (Round 1 May 8-15, 2020)

Sample size, tracking and attrition: Sample includes 1,012 respondents contacted in the second round of a panel of 1,507.

Sampling Weights: Post-stratification weights are computed to adjust for differential attrition between the first and second rounds of the RDD panel, weighting on gender, region, and educational attainment.

IRB Approval: This research was approved via IPA IRB Protocol 15582.

India, Coping with COVID-19 in Slums: Evidence from India Subnational sample, Nova School of Business and Economics, The Institute for Fiscal Studies, University of St. Andrews

COVID-19 Experience

- First confirmed case: January 30, 2020
- Number of confirmed cases: 198,370 as of June 1, 2020
- Number of deaths: 5,608 as of June 1, 2020

Target Population: Random subset of slum populations in Lucknow and Kanpur, Uttar Pradesh, India. Socio-economic variables are only collected for a representative sample of the population relying on community toilets or open defecation to fulfil their sanitation needs.

Original Study Design: Randomized controlled trial, with complete census of households within 142 slums (September to December 2017), and a series of household and caretaker surveys, objective measurements, incentivized behavioural measurements, and a Structured Community Activity, collected for a sub-set of 100 slums between April 2018 and September 2019.

Intervention: Catchment areas of CTs were randomly allocated to two interventions. The first intervention aimed at community toilet improvements by offering caretakers the choice of a grant to be spent for improvements in the facility. Following the grant, caretakers were offered a large

financial reward conditional on the cleanliness of the facility. The second intervention added to this CT improvement awareness creation among potential users through face-to-face information sessions, leaflets, monthly reminders using voice messages sent to mobile phones, and posters hung in the CTs.

Sampling Frame: A two-step sampling was applied, first, study households from the main study sample were sampled, then households from the whole slum population were added.

Survey Dates: Baseline: June to July 2020, Follow-up 1: October to November 2020, Follow-up 2: December 16, 2020 to January 18, 2021.

Sample size, tracking and attrition: 3,991 households, with a mean of 28 households per cluster (142). Non-response Baseline: 25%, Attrition rate Baseline to Follow-up (1 and 2): 13%, Randomly selected replacement households for Follow-up (1 and 2): 1,277.

Sampling Weights: Included

IRB Approval: Approval was secured from London School of Economics (REC ref. 1132). The pre-analysis plan was registered on the AEA RCT registry (RCT ID AEARCTR-0006564).

Mozambique Subnational sample, International Growth Center, Nova School of Business and Economics

COVID-19 Experience

- First confirmed case: March 22, 2020
- Number of confirmed cases: 12,777 as of October 30, 2020
- Number of deaths: 91 as of October 30, 2020

Target Population: Microentrepreneurs in urban markets of Maputo and household heads from the province of Cabo Delgado.

Original Study Design: Initial data were collected in-person in two different studies. For microentrepreneurs in Maputo, the data were collected between October 2013 and April 2014 (baseline), and between July and November 2015 (endline).² For household heads in Cabo Delgado, the data were collected in-person between August and September 2016 (baseline), and between August and September 2017 (endline).³

Intervention: The first study was dedicated to analyzing the impacts of interventions targeting microentrepreneurs in urban markets on financial inclusion and literacy. The second study focused on the role of information to counteract the political resource curse after a substantial natural gas discovery.

Sampling Frame: The first initial sample was selected by in-field random sampling in 23 urban and periurban markets in Maputo and Matola. Stratification was based on the gender of the respondent

²Original study: http://catiabatista.org/bsv_mm_urban.pdf

³Original study: <https://www.aeaweb.org/articles?id=10.1257/aer.20190842>

and on the type of establishment (stall vs. store). The second initial sample was selected to be representative of 206 communities in the province of Cabo Delgado, randomly drawn from the list of all 421 polling locations in the sampling frame, stratified on urban, semiurban, and rural areas. This survey in this paper was done by phone.

Survey Dates: October 30 to November 21, 2020 (Maputo) and November 6 to November 30, 2020 (Pemba).

Sample size, tracking and attrition: 554 microentrepreneurs from Maputo and 308 households from Cabo Delgado.

Sampling Weights: N/A

IRB Approval: The approval was secured from Universidade Nova de Lisboa on July 14, 2020.

Nepal, Western Terai Panel Survey (WTPS) Subnational sample, Yale University, Yale Research Initiative on Innovation and Scale (Y-RISE)

COVID-19 Experience

- First confirmed case: January 23, 2020
- Number of confirmed cases: 233,452 as of December 1, 2020
- Number of deaths: 1,529 as of December 1, 2020

Target Population: Rural households in the districts of Kailali and Kanchanpur.

Original Study Design: Initial baseline data was collected in-person in July of 2019, and 5 rounds of phone survey data were collected between August 12, 2019 and January 4, 2020.

Sampling Frame: The phone survey sample includes 2,636 rural households in the districts of Kailali and Kanchanpur, which represent the set of households that responded to phone surveys from an original sample of 2,935 households. This sample was constructed by randomly sampling 33 wards from 15 of the 20 sub-districts in Kailali and Kanchanpur and selecting a random 97 villages from within those wards. At the time of baseline data collection in July of 2019, 7 of these 97 villages were dropped from the sample due to flooding. Households belong to the bottom half of the wealth distribution in these villages, as estimated by a participatory wealth ranking exercise with members of the village.

Survey Dates: December 1st - December 11, 2020

Sample size, tracking and attrition: 1,392 households

IRB Approval: This research was approved via Yale University IRB Protocol 2000025621.

Nigeria Subnational sample, WZB Berlin Social Science Center, University of Illinois Chicago

COVID-19 Experience

- First confirmed case: February 28, 2020
- Number of confirmed cases: 65,693 as of November 18, 2020
- Number of deaths: 1,163 as of November 18, 2020

Target Population: Christian and Muslim men and women, age 18 and above, living in Kaduna state, Nigeria.

Original Study Design: Initial data was collected from a subset of the sample in December 2019 (in person survey) and July - Aug 2020 (phone survey) as part of an experiment testing the effects of a brief radio program on inter-religious animus. A random walk procedure and random sampling were used within households to recruit a representative sample of adults in Kaduna town. The rest of the sample was recruited for the study in Aug 2020 by purchasing phone lists for residents of Kaduna State.

Intervention: The study examines the effects of a radio program and a TV drama on inter-religious animus. The subset of the sample in the radio study was randomly assigned to listen to a brief radio program on one of the following topics: (1) an inter-religious storyline, (2) an intra-religious storyline, and (3) a message about maintaining safe health practices. All respondents in the sample participated in a study examining the effect of viewing an inter-religious storyline unfolding over a full season of a popular TV drama, Dadin Kowa. The season aired from Aug - Oct 2020. A third of the sample were encouraged to watch Dadin Kowa, a third were encouraged to watch the TV station Africa Magic Hausa at the same time Dadin Kowa aired, and a third were in the treatment-as-usual group. All participants received a weekly incentivized SMS quiz from Aug - Oct 2020.

COVID-19 Survey Design: This survey is not primarily about COVID-19, but was designed as an endline survey to follow the TV drama intervention described above. The goal of this survey is to measure a range of attitudinal outcomes related to Christian-Muslim relations (including prejudice, intergroup threat perceptions, dehumanization, and support for the use of violence, among others). We included nine of the standardized COVID-19 vaccine-related questions collected specifically for this vaccine acceptance study in the final module of the endline survey.

Sampling Frame: 950 respondents in the sample were recruited in person through a random sampling procedure in the Kaduna metropolitan area (pre-COVID). The remaining 1,700 respondents were recruited into the study over the phone from lists of phone numbers of Kaduna state residents that were purchased from a private vendor.

Survey Dates: November 18 - December 18, 2020.

Sample size, tracking and attrition: All 1,834 individuals who completed the endline survey are included.

Sampling Weights: N/A

IRB Approval: This study was reviewed by the IRB at the University of Pennsylvania (Protocol 834548), and it was determined on November 20, 2019 to meet the criteria for review exemption (45 CFR 46.104, category #2).

Pakistan

COVID-19 Experience

- March 6: First confirmed case: February 26, 2020
- Number of confirmed cases: 271,887 as of July 24, 2020
- Number of deaths: 5,787 as of July 24, 2020

Pakistan, Economic Vulnerability Assessment (EVA) Subnational sample, Sheikhpura Police Study Sample, Institute of Development and Economic Alternatives, Lahore University of Management Science, London School of Economics, Princeton University (Pakistan 1)

Target Population: A representative sample of adults from 108 of 151 police beats in Sheikhpura and Nankana districts of Punjab Province.

Original Study Design: N/A

COVID-19 Survey Design: The EVA survey involved calls to all households in the stratified random sample for the policing study midline survey.

Sampling Frame: Households in Sheikhpura and Nankana districts.

Survey Dates: July 24 to September 9, 2020

Sample size, tracking and attrition: Sample includes 1,473 respondents.

Sampling Weights: Post-stratification weights are computed to adjust for the sampling process, which involved stratifying first on 27 police stations, then within each police station on beats, then PPS sampling within beats using Asiapop population data.

IRB Approval: This research was approved via Princeton University IRB Protocol 7250.

Pakistan, Economic Vulnerability Assessment (EVA) Subnational sample (Pakistan 2)

Target Population: All possible mobile phone numbers (in the province of Punjab) generated based on the local mobile phone number structure in Pakistan.

Original Study Design: N/A

COVID-19 Survey Design: The EVA survey involved making calls to individuals in Punjab based on random digit dialing.

Sampling Frame: Individuals with mobile phones in Punjab.

Survey Dates: September 2 to October 13, 2020

Sample size, tracking and attrition: Sample includes 1,492 respondents.

Sampling Weights: N/A.

IRB Approval: This research was approved by Lahore University of Management Sciences IRB Protocol LUMS-IRB/07012020SA.

Rwanda, Research for Effective COVID-19 Responses (RECOVR) National RDD Sample, Innovations for Poverty Action (IPA)

COVID-19 Experience

- First confirmed case: March 14, 2020
- Total cases: 5,017 as of October 22, 2020
- Total deaths: 34 as of October 22, 2020

Target Population: A random sample of all numerically possible mobile phone numbers in the country, based on national communications authority number allocation plans.

Original Study Design: N/A

COVID-19 Survey Design: Phone survey

Sampling Frame: Numbers were called via random digit dialing (RDD), stratified by mobile network operator market share.

Survey Dates: October 22 to November 5, 2020 (Round 1 June 4 -12, 2020)

Sample size, tracking and attrition: Sample includes 1,355 respondents contacted in the second round of a panel of 1,480.

Sampling Weights: Post-stratification weights are computed to adjust for differential attrition between the first and second rounds of the RDD panel, weighting on gender, region, and educational attainment.

IRB Approval: This research was approved via IPA IRB Protocol 15591, Rwanda National Institute for Scientific Research permit No.0856/2020/10/NISR; and Rwanda National Ethics Committee approval No.16/RNEC/2020.

Russian Federation, Research on COVID-19 in Russia's Regions (RoCiRR) Subnational sample, International Center for the Study of Institutions and Development (HSE University, Moscow, Russia) and Economics Department of Ghent University, WZB Berlin Social Science Center, Columbia University

COVID-19 Experience

- First confirmed case: January 31, 2020
- Number of confirmed cases: 1,720,063 as of November 6, 2020
- Number of deaths: 29,654 as of November 6, 2020

Target Population: Adult internet users who reside in one of 61 federal subjects (federal cities, oblasts, republics, krais and autonomous okrug) of Russia. The regions included in the study are Republics: *Bashkortostan, Karelia, Komi, Mariy El, Mordovia, Tatarstan, Udmurtia, Chuvashia*. Krais: *Altai, Krasnodarsky, Krasnoyarsky, Permsky, Primorsky, Stavropolsky, Khabarovsk*. Oblasts: *Arkhangelsk, Astrakhan, Belgorod, Bryansk, Vladimir, Volgograd, Vologda, Voronezh, Ivanovo, Irkutsk, Kaliningrad, Kaluga, Kemerovo, Kirov, Kostroma, Kurgan, Kursk, Leningrad, Lipetsk, Moscow, Murmansk, Nizhny Novgorod, Novgorod, Novosibirsk, Omsk, Orenburg, Orel, Pskov, Penza, Rostov, Ryazan, Samara, Saratov, Sverdlovsk, Smolensk, Tambov, Tver, Tomsk, Tula, Tyumen, Ulyanovsk, Chelyabinsk, Yaroslavl*. Other: *Moscow, Saint Petersburg, Khanty-Mansiysk Autonomous Okrug – Ugra*. The remaining 24 federal subjects were excluded from the study due to inability to enroll sample size with desired characteristics (sample size, age, gender and education group composition) and account for less than 14% of the total adult population of Russia.

Original Study Design: N/A

COVID-19 Survey Design: The study was designed to measure the impact of pandemics on Russians, mostly those who live in cities with more than 100,000 residents. It contains a number of questions on the personal experience, norms and values, trust in government institutions, provision of social services, and mass media use. Region and geolocality of every respondent are recorded.

Sampling Frame: In total 25,558 respondents received the module on vaccine acceptance. The sample was enrolled from the pool of Russian online survey company OMI (Online Market Intelligence). The sampling was specifically targeted at having a minimum of 150 respondents in each of the 61 regions and including respondents from all the main age and gender groups within each region. Respondents were also selected so that at least 40% of respondents did not have higher education, in accordance with higher education rates in Russia. Out of 25,558 recruited respondents, 22,125 completed the survey. Among 22,125 respondents who completed the survey, 20,821 were enrolled from the general pull of the survey company respondents, while the remaining 1,304 respondents were enrolled among residents of cities with populations below 100,000 and rural areas.

Survey Dates: November 6 - December 1, 2020

Sample size, tracking and attrition: 22,125 respondents who completed the survey with the vaccine acceptance module included.

Sampling Weights: Post-stratification weights are computed to match marginal distributions of age, gender and education among the adult population of Russia with target proportions coming from the 2019 Yearbook and 2015 Microcensus released by Russian Federal Bureau of National Statistics (Rosstat).

IRB Approval: This study was approved via Columbia University IRB Protocol IRB-AAAT4453.

Sierra Leone

COVID-19 Experience

- First confirmed case: March 20, 2020
- Total cases: 2,252 as of October 2, 2020 and 3,030 as of January 20, 2021
- Total deaths: 72 as of October 2, 2020 and 77 as of January 20, 2021

Sierra Leone, Research for Effective COVID-19 Responses (RECOVR) National RDD Sample, Innovations for Poverty Action (IPA) (Sierra Leone 1) **Target Population:** A random sample of all numerically possible mobile phone numbers in the country, based on national communications authority number allocation plans.

Original Study Design: N/A

COVID-19 Survey Design: Numbers were called via random digit dialing (RDD), stratified by mobile network operator market share

Sampling Frame: All active mobile phone numbers in Sierra Leone.

Survey Dates: October 2-19, 2020 (Round 1 May 27 to June 15, 2020)

Sample Size, tracking and Attrition: Sample includes 1,070 respondents contacted in the second round of a panel of 1,304.

Sampling Weights: Post-stratification weights are computed to adjust for differential attrition between the first and second rounds of the RDD panel, weighting on gender, region, and educational attainment.

IRB Approval: This research was approved via IPA IRB Protocol 15592, and Sierra Leone Ethics and Scientific Review Committee approval (no approval number, letter available upon request).

Sierra Leone, Towns that are Candidates for Rural Electrification Nation-wide sample, International Growth Centre (IGC), Wageningen University & Research, Yale Research Initiative on Innovation and Scale (Y-RISE), WZB Berlin Social Science Center and Columbia University (Sierra Leone 2) **Project Title:** Sierra Leone Rural Electrification (SLRE)

Target Population: Households in 195 rural towns across all 14 districts of Sierra Leone. Of these, 97 villages were selected to benefit from an electrification program.

Original Study Design: Initial baseline data was collected during late 2019 and early 2020 as part of a study to assess the impact of Rural Electrification in rural towns in Sierra Leone.

Intervention: The Government of Sierra Leone (GoSL) in collaboration with the United Nations Office for Project Services (UNOPS) and international donors is implementing the Rural Renewable Energy Project (RREP). In its first wave, during 2017, the project provided stand-alone solar photovoltaic powered mini-grids to 54 communities across the country. Construction of mini-grids in a further 43 towns is ongoing. In RREP communities, engineers construct 6kW–36kW power

mini-grids that provide reliable power year-round. Electricity is free for schools and clinics. Residential and commercial users can acquire connections from commercial operators.

Village Sampling Frame: Household data was collected in 195 towns across all 12 districts of Sierra Leone. The GoSL selected 97 towns with (planned) mini-grids. We used Propensity Score Matching to select 98 control communities. Within communities, respondents were randomly selected from a census roster stratified by occupation status of farmers, business owners and other occupations [47 percent, 47 percent and 7 percent]. In each village, the intended sample was 43 households (20 farmers, 20 businesses, 3 others). Data was collected during June–July (108 communities) and November–December 2019 (87 communities). If a household on the sampling list was not available on the village visit day, we had a randomly sampled list of replacement households to survey. The replacement household would be the same occupation as the sampled household would have been so the sample ratio of 20-20-3 still held in each community.

COVID-19 Survey Design: The goal was to assess households' degree of economic vulnerability in the face of the COVID-19 pandemic.

Sampling Frame: The COVID-19 survey data comprises 2,110 respondents from 186 towns from the original baseline survey. Phone surveys were attempted to all 195 rural communities from the baseline survey. The total baseline household sample comprised 7047 respondents. We recontacted all baseline respondents that listed a phone number (4,594 respondents) and obtained informed consent for the phone survey. We implemented several waves of the phone survey, recontacting a respondent about every month. In wave 7, we added questions related to Vaccine Acceptability.⁴

Survey Dates: October 7, 2020 to January 20, 2021 (earlier rounds included Wave 1: April 29-May 15; Wave 2: May 15-June 4; Wave 3: June 5-June 17; Wave 4: June 17-June 30; Wave 5: July 1-August 8; Wave 6: August 19-October 1). The median survey time was 33 minutes.

Sample size, tracking and attrition: Data collection took place between October 7 and January 20, 2021 with 2,110 respondents, in 186 towns for a tracking rate of 46 percent.

Sampling Weights: None

IRB Approval: Approval was secured from Sierra Leone Ethics and Scientific Review Committee (SLERC 2904202) and Wageningen University (24062020).

Uganda

COVID-19 Experience

- First confirmed case: March 21, 2020
- Total cases: 741 as of June 18, 2020 and 6,468 as of September 21, 2020
- Total deaths: 0 as of June 18, 2020 and 63 as of September 21, 2020

⁴The data was first reported in <https://www.theigc.org/wp-content/uploads/2020/05/Meriggi-et-al-Data-Brief-2020.pdf>

Uganda Subnational sample, International Growth Center, Trinity College Dublin, Stockholm School of Economics and Misum, Institute for International Economic Studies, Stockholm University (Uganda 1) **Target Population:** Women from semi-rural and rural villages across 13 districts in Uganda (Iganga, Kayunga, Mbale, Mityana, Apac, Dokolo, Gulu, Adjumani, Koboko, Maracha, Nebbi, Soroti, Kumi).

Original Study Design: Initial baseline data was collected in 2016 as part of a large cluster randomized controlled trial, with the aim of selecting households likely to have children during the study period. Four criterias for selection were thus used, in descending order of importance: the household has a woman that is currently pregnant, or aged 16-30 years old, with a young child less than three years old, and/or married (formally or informally). In each household, the respondent was chosen as the female household head or the primary female health care giver of the household if the household head could not be found.

COVID-19 Survey Design: The data was collected through multiple rounds of phone surveys. The variable measuring age was constructed by approximation, using the baseline data from 2016 and adding 4 years to the 2016 measure. When the baseline respondent was replaced, the initial age information was deleted.

Sampling Frame: Households were selected within 500 clusters (the village of the household).

Survey Dates: September 21 to December 06, 2020.

Sample size, tracking and attrition: Out of 2,743 respondents, 1752 were included, provided that they answered the main question about vaccine uptake.

Sampling Weights: None.

IRB Approval: Mildmay Uganda Research Ethics Committee (protocol number 0109-2015) on September 21, 2020.

Uganda Subnational sample, WZB Berlin Social Science Center and Columbia University, NYU Abu Dhabi, Innovations for Poverty Action (IPA) (Uganda 2)

Target Population: All residents of Kampala who are Ugandan citizens, above the age of 18, and agree in principle to attend a short citizen consultative meeting.

Original Study Design: Baseline data was collected between July and October 2019 for an intervention that randomized citizen attendance to a set of 188 consultative meetings organized across Kampala. The meetings were organized to collect citizen preferences for the design of a forthcoming municipal citizen charter. The study also aimed to assess patterns of political inequality in meeting participation, dynamics, and outcomes, as well as study the subsequent effects on prosociality of being incorporated in this participatory process. 1/3 of the sample was randomly allocated to control, while 2/3 of respondents were invited to attend a consultative meeting. The consultations took place between November 2019 and February 2020 across Kampala divisions.

Intervention: The intervention consisted of attendance at the consultative meeting organized a few months after baseline data collection. A further randomization allocated 1/2 of the invited participants to a meeting moderated by a local bureaucrat, while the remaining ones attended a meeting moderated by a neutral discussion leader.

COVID-19 Survey Design: The COVID-19 survey sample comprises the 2,189 respondents to the baseline who were selected on the basis of their residence in the city. Having received permission to re-contact these individuals, we coordinated a 3-wave panel throughout the summer and fall of 2020, with respondents contacted via phone. The goal was to assess households' degree of economic vulnerability in the face of the COVID-19 pandemic and respondents' evaluations of performance of political actors in tackling the pandemic.

Sampling Frame: The 2,189 respondents to the baseline were randomly selected from a sampling frame of all buildings in Kampala, for which information about their geographical coordinates was available. After randomly selecting a set of candidate structures, interviewers sampled respondents from the subset of structures that were residential.

Survey Dates: Wave 1: June 18–July 23. Wave 2: September 4–29. Wave 3: November 23–December 12.

Sample size, tracking and attrition: Of the 2,189 respondents which we aimed to contact, we were able to reach 1,333 in Wave 1, 1,289 in Wave 2, and 1,366 in Wave 3. Wave 3 contained the COVID-19 vaccine module presented in this analysis.

Sampling Weights: None.

IRB Approval: The study was approved by IPA Global IRB (protocol number 15018) on May 29, 2020; WZB Berlin Social Science Center Ethics Review Board (protocol number 2020/0/91) on June 10, 2020; NYU Abu Dhabi IRB (protocol number HRPP-2020-64) on May 27, 2020; MIT Committee on the Use of Humans as Experimental Subjects (protocol number 2005000155) on June 3, 2020; and by the Mildmay Uganda Research Ethics Committee (protocol number 0604-2019) on June 11, 2020.

United States of America Nation-wide sample, WZB Berlin Social Science Center, Cornell University, Tufts University

COVID-19 Experience

- First confirmed case: January 20, 2020
- Total cases: 14,499,637 as of December 4, 2020
- Total deaths: 281,678 as of December 4, 2020

Target Population: Nation-wide sample of adult internet users recruited through the market research firm Lucid.

Original Study Design: N/A

Intervention: N/A

COVID-19 Survey Design: This survey was part of a panel study on attitudes toward COVID-19 technologies and public health surveillance.

Sampling Frame: The Lucid Marketplace is an automated marketplace that connects researchers with willing online research participants. Lucid partners with a network of companies that maintain relationships with research participants by engaging them with research opportunities. While Lucid does not provide probability samples of the U.S. adult population, its quota samples approximate the marginal distributions of key demographic characteristics. Recent validation exercises have found that Lucid samples approximate nationally representative samples in terms of demographic characteristics and survey experiment effects.⁵

Survey Dates: December 4-5, 2020

Sample size, tracking and attrition: 1,959 individual online surveys. In the main question regarding intention to take the vaccine, approximately 10% of respondents (184) did not answer

Sampling Weights: Post-stratification weights are computed to match marginal population distributions of income, age, education, gender, race and region among the US adult population, with target proportions based on the 2018 American Community Survey.

IRB Approval: This study received approval from the Cornell University IRB under Protocol #2004009569.

⁵See for instance: <https://journals.sagepub.com/doi/10.1177/2053168018822174>